Formulari Ubat ubatan kkm

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY weeks as tolerated. Maximum: 10 mg/kg/day1102 Nifedipine 10 mg Capsule C08CA05000C1001 B Hypertension 10 - 30 mg 3 times daily. XX B Maximum: 120 - 180 mg per Hypertension day1103 Nifedipine 10 mg Tablet C08CA05000T1001X Initial dose of 10 mg twice X For the treatment of adult daily. Usual range 10 - 30 mg patients with newly 3 times daily. Maximum: 1201104 Nilotinib 150mg capsule L01XE08110T1001X A* diagnosed Philadelphia - 180 mg per day. Elderly: X chromosome positive chronic Dose reduction may be myelogenous leukemia in the necessary.1105 Nilotinib 200 mg Capsule L01XE08110C1001X A* chronic phase (CP). 300mg twice daily. Dose X Treatment of chronic phase adjustments or and accelerated phase modifications:For1106 Nimodipine 10 mg/50 ml C08CA06000P9901 A* Philadelphia chromosome neutropenia & Infusion Solution XX positive chronic myelogenous thrombocytopenia leukaemia (CML) in adults1107 Nimodipine 30 mg Tablet C08CA06000T1001X A* who: 400 mg twice daily, 12 hours X i) Failed imatinib ie no apart. No food should be cytogenic response and no taken two hours before and 11108 Nitrazepam 5 mg Tablet N05CD02000T1001 B haematological response by hour after taking the dose XX B 12 months ii) Have molecular resistance IV infusion of 1 mg/hour for a1109 Nitrofurantoin 100 mg J01XE01000T1002X to Imatinib as shown by period of 2 hours (about 15 Tablet X molecular mutation studies mcg/kg/hour). IV therapy iii) Are intolerant to Imatinib should be started no later than 4 days after Prophylaxis & treatment of haemorrhage & continue for ischaemic neurological up to 10 - 14 days deficits caused by cerebral vasospasm following 360 mg daily in divided doses subarachnoid haemorrhage for 7 days of aneurysmal origin 5 - 10 mg at bedtime. Prophylaxis & treatment of ELDERLY or debilitated 2.5 - ischaemic neurological 5 mg. CHILD not deficits caused by cerebral recommended. Increasing vasospasm following slowly according to response subarachnoid haemorrhage Acute uncomplicated urinary of aneurysmal origin tract infections Adult: 50-100 mg 4 times daily for 7 days. Epilepsy (infantile spasms) Uncomplicated lower urinary tract infectionsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 201 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1110 Nonacog alfa 1000 IU B02BD09000P4003X Treatment and prophylaxis of Dual-release preparation: injection X A* bleeding in patients with 100 mg bid. Child: >3 mth A* haemophilia B (congenital and older children: 3 mg/kg1111 Nonacog alfa 2000 IU B02BD09000P4004X A* factor IX deficiency) daily in 4 divided doses. injection X A* Prophylaxis of uncomplicated Treatment and prophylaxis of urinary tract infections Adult:1112 Nonacog alfa 250 IU B02BD09000P4001X bleeding in patients with 50-100 mg at bedtime. Child: injection X haemophilia B (congenital >3 mth and older children: 1 factor IX deficiency) mg/kg once daily.1113 Nonacog alfa 500 IU B02BD09000P4002X injection X Treatment and prophylaxis of Number of factor IX units bleeding in patients with required = body weight (kg) x haemophilia B (congenital desired factor IX increase (% factor IX deficiency) or units/dL) x reciprocal of observed recovery (units/kg Treatment and prophylaxis of per units/dL). Average dose bleeding in patients with for secondary prophylaxis for haemophilia B (congenital previously treated adult factor IX deficiency) patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 daysUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 202 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Noradrenaline Acid Tartrate C01CA03123P3001 A Septic shock and shock Infuse and titrate to desired1114 (Norepinephrine Bitartrate) XX where peripheral vascular pressure response. Range: resistance is low 0.05 - 0.5 mcg/kg/minute 1 mg/ml Injection1115 Norethisterone 0.35 mg G03AC01000T1001 C+ Contraception 1 tablet daily starting on the Tablet XX first day of the menstrual bleeding By deep IM injection only. First injection is within first 51116 Norethisterone Enanthate G03AC01257P3001 B Contraception days of the cycle. The next 3 200 mg/ml Injection XX injections are given at 8 weeks interval after which the injection interval should be extended to 12 weeks ADULT and CHILD more S01AX12000D2001X Superficial infections of the than 1 year : 1-2 drops 4 X eye (Pseudomonas times daily. First day : 1 - 21117 Norfloxacin 0.3% Eye Drops A* aeruginosa and MRSA) and drops two hourly during its adnexae waking hours (depending on severity) Apply liberally to affected area twice daily or as required. After lesion has1118 Nystatin 100,000 units/g D01AA01000G1001 C Prevention and treatment of disappeared continue Cream XX cutaneous infections caused treatment for 10 days to by Candida albicans prevent relapses. Nail infection: Cut nails as short as possible. Apply cream once daily until growth of new nail has set in Apply liberally to affected area twice daily or as required. After lesion has Prevention and treatment of disappeared continue1119 Nystatin 100,000 units/g D01AA01000G5001 C cutaneous or mucocutaneous treatment for 10 days to Ointment XX infections caused by Candida prevent relapses. Nail albicans infection: Cut nails as short as possible. Apply cream once daily until growth of new nail has set in1120 Nystatin 100,000 units/ml A07AA02000L8001X B Prevention and treatment of NEWBORN: 50,000-100,000 Suspension X candidiasis of the skin and units daily. CHILD up to 5 mucous membranes, years: 100,000 -500,000 protection against candidas units 6 hourly. CHILD up to overgrowth during 6-12 years and ADULT: antimicrobial /corticosteroid 500,000-1,000,000 units 3 to therapy and as selective 4 times daily decontamination regimens Prevention and treatment of candidiasis of the skin and1121 Nystatin 500,000 units A07AA02000T1001X B mucous membranes, ADULT: 500,000 -1,000,000 Tablet X protection against candidas units 6 hourly, according to overgrowth during severity of infections. CHILD: antimicrobial /corticosteroid 100,000-500,000 units 6 therapy and as selective hourly decontamination regimensUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 203 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1122 Octreotide 0.05 mg/ml H01CB02122P3002 i) Acromegaly i, ii and iii) Initially 0.005 - 0.1 Injection XX A ii) Treatment of patients with mg SC 1 - 2 times daily, symptoms associated with increase gradually up to 0.1 -1123 Octreotide 0.1 mg/ml H01CB02122P3001 A gastro-entero-pancreatic 0.2 mg 3 times daily Injection XX endocrine tumours iv) 0.1 mg 3 times daily for 7 A* iii) Carcinoid tumours with consecutive days, starting on1124 Octreotide Acetate 20 mg H01CB02122P2001 features of the carcinoid the day of operation, at least Injection XX syndrome, VIPomas, 1 hour before laparotomy glucagonomas, v) 25 mcg/hour for 5 days by gastrinomas/Zollinger-Ellison continous IV infusion syndrome, GRFomas, insulinomas i, ii and iii) Initially 0.005 - 0.1 iv) Prevention of mg SC 1 - 2 times daily, complications following increase gradually up to 0.1 - pancreatic surgery 0.2 mg 3 times daily v) Emergency management iv) 0.1 mg 3 times daily for 7 of bleeding gastro- consecutive days, starting on eosophageal varices in the day of operation, at least patients with cirrhosis 1 hour before laparotomy i) Acromegaly v) 25 mcg/hour for 5 days by ii) Treatment of patients with continous IV infusion symptoms associated with gastro-entero-pancreatic 10 - 30 mg every 4 weeks as endocrine tumours deep intragluteal injection iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, GRFomas, insulinomas iv) Prevention of complications following pancreatic surgery v) Emergency management of bleeding gastro- eosophageal varices in patients with cirrhosis i) Adjunctive treatment for active acromegaly (second/third line therapy in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor). ii) Treatment of symptoms associated with functional gastro-entero-pancreatic endocrine tumours. iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, Glucagonomas, Gastrinomas/Zollinger-Ellison syndrome, Insulinomas, forUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 204 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1125 Octreotide Acetate 30 mg H01CB02122P2002 pre-operative control of 10 - 30 mg every 4 weeks as Injection XX A* hypoglycemia and for deep intragluteal injection maintenance therapy,1126 Ofloxacin 0.3% Otic S02AA00000D1001X A/KK GRFomas. CHILD: 1 - 12 years: 5 drops Solution X A i) Adjunctive treatment for twice daily for 10 days. A active acromegaly ADULT and CHILD over 121127 Ofloxacin 100 mg Tablet J01MA01000T1001X A* (second/third line therapy in years: 6 - 10 drops twice X whom surgery or daily and remain in the ear1128 Ofloxacin 200 mg Injection radiotherapy is inappropriate about 10 minutes J01MA01000P4001X or ineffective- based on level1129 Olanzapine 10 mg X of growth hormone and high i) 400 mg/day Disintegrating Tablet IGF-1 and residual pituitary ii) 400 mg twice daily N05AH03000T4002X tumor). iii) 200 mg twice daily X ii) Treatment of symptoms associated with functional 200 mg IV twice daily for 3 - gastro-entero-pancreatic 5 days followed with 200 mg endocrine tumours. tablet twice daily for 3 - 5 iii) Carcinoid tumours with days as maintenance dose (if features of the carcinoid necessary) syndrome, VIPomas, i) 5 - 10 mg once daily, Glucagonomas, increase to 10 mg once daily Gastrinomas/Zollinger-Ellison within 5 - 7 days, adjust by 5 syndrome, Insulinomas, for - 10 mg/day at 1 week pre-operative control of intervals, maximum 20 hypoglycemia and for mg/day maintenance therapy, ii) 10 - 15 mg once daily, GRFomas. increase by 5 mg/day at Acute otitis media with intervals of not less than 24 tympanostomy tubes, chronic hours. Maintenance 5 - 20 suppurative otitis media with mg/day; maximum 20 mg/day perforated tympanic membranes and otitis externa i) As second-line treatment of leprosy ii) As second-line treatment for tuberculosis and multidrug resistant tuberculosis (MDR- TB) iii) Sequential therapy for UTI and pyelonephritis Sequential therapy for UTI and pyelonephritis i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorderUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 205 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE1130 Olanzapine 10 mg Tablet N05AH03000T1002X CATEGORY i) Acute and maintenance i) 5 - 10 mg once daily,1131 Olanzapine 5 mg Tablet X A* treatment of schizophrenia increase to 10 mg once daily and other psychoses where within 5 - 7 days, adjust by 51132 Olanzapine 5mg N05AH03000T1001X A* positive and or negative - 10 mg/day at 1 week Disintegrating Tablet X symptoms are prominent intervals, maximum 20 A* ii) Short-term use for acute mg/day1133 Olive Oil Ear Drops N05AH03000T4001X C mania episodes associated ii) 10 - 15 mg once daily, X A* with Bipolar 1 disorder increase by 5 mg/day at1134 Olopatadine hydrochloride intervals of not less than 24 ophthalmic solution 0.2% S02DC00000D1001 A* i) Acute and maintenance hours. Maintenance 5 - 20 XX treatment of schizophrenia mg/day; maximum 20 mg/day Omalizumab 150 mg and other psychoses where i) 5 - 10 mg once daily,1135 (powder and solvent for S01GX09110D2002 positive and or negative increase to 10 mg once daily XX symptoms are prominent within 5 - 7 days, adjust by 5 solution) ii) Short-term use for acute - 10 mg/day at 1 week R03DX05000P3001 mania episodes associated intervals, maximum 20 XX with Bipolar 1 disorder mg/day ii) 10 - 15 mg once daily, i) Acute and maintenance increase by 5 mg/day at treatment of schizophrenia intervals of not less than 24 and other psychoses where hours. Maintenance 5 - 20 positive and or negative mg/day; maximum 20 mg/day symptoms are prominent i) 5 - 10 mg once daily, ii) Short-term use for acute increase to 10 mg once daily mania episodes associated within 5 - 7 days, adjust by 5 with Bipolar 1 disorder - 10 mg/day at 1 week intervals, maximum 20 Impacted wax softener mg/day ii) 10 - 15 mg once daily, Temporary prevention of increase by 5 mg/day at ocular itching due to allergic intervals of not less than 24 conjunctivitis hours. Maintenance 5 - 20 i) For adults and adolescents mg/day; maximum 20 mg/day (≥12 years), for severe 3 - 4 drops 3 - 4 or as persistent allergic asthma directed whose symptoms are inadequately controlled with One drop in each affected inhaled corticosetroids eye once a day ii) For Children (6 to <12 years of age): As add-on i) Adult & adolescent ≥12 yr, therapy to improve asthma 150-375 mg SC every 2-4 control with severe persistent wk, according to body wt & allergic asthma who have baseline serum total IgE positive skin test or in vitro level.. For subcutaneous reactivity to a perennial aero administration only. Do not allergen and frequent administer by the intravenous daytime symptoms or night- or intramuscular route. time awakenings and who ii) Appropriate dose and have had multiple dosing frequency of documented severe asthma omalizumab is determined by exacerbations despite daily baseline IgE (IU/ml), measured before the start of treatment, and body weight (kg). Prior to initial dosing, patients should have their IgE level determined for their dose assignment. Based on these measurements 150-Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 206 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 375mg in 1 -3 injections may high-dose inhaled be needed for each corticosteroids, plus a long- administration. Patients acting inhaled beta 2 agonist whose baseline IgE levels or body weight in kilograms are1136 Omeprazole 10 mg Capsule A02BC01000C1001 Only for : outside the limits of the XX i) Reflux oesophagitis dosing table should not be ii) For eradication of given omalizumab. For Helicobacter pylori infection subcutaneous administration A/KK iii) Benign peptic ulcer not only. responding to conventional i) 20 - 80 mg 1 - 2 times daily therapy up to 8 - 12 weeks iv) Zollinger-Ellison ii) 20 mg twice daily in Syndrome combination with any of the 2 antibiotics (clarithromycin1137 Omeprazole 20 mg Capsule A02BC01000C1002 Only for : 500 mg twice daily, XX i) Reflux oesophagitis amoxicillin 1 g twice daily or ii) For eradication of metronidazole 400 mg twice Helicobacter pylori infection daily) for 1 - 2 weeks A/KK iii) Benign peptic ulcer not iii) 20 mg once daily for 4 - 6 responding to conventional weeks therapy iv) ADULT: 20 - 120 mg once iv) Zollinger-Ellison daily adjusted according to Syndrome the patient's response. CHILD 0.4 - 0.8 mg/kg/day Only for : i) 20 - 80 mg 1 - 2 times daily i) Reflux oesophagitis up to 8 - 12 weeks ii) 20 mg twice daily in ii) For eradication of combination with any of the 2 antibiotics (clarithromycin1138 Omeprazole 40 mg Injection A02BC01000P4001X A* Helicobacter pylori infection 500 mg twice daily, X iii) Benign peptic ulcer not amoxicillin 1 g twice daily or responding to conventional metronidazole 400 mg twice daily) for 1 - 2 weeks therapy iii) 20 mg once daily for 4 - 6 weeks iv) ADULT: 20 - 120 mg once daily adjusted according to the patient's response. CHILD 0.4 - 0.8 mg/kg/day i) 40 mg IV once daily when oral therapy is inappropriate ii) 40- 160 mg by IV in single or divided doses iv) Zollinger-Ellison SyndromeUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 207 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i)8 mg given by IV infusion i) Prevention of nausea and over 15 minutes or by IM immediately before treatment vomiting induced by followed by 8 mg orally every 12 hours for up to 5 days.1139 Ondansetron 2 mg/ml A04AA01110P3001X A chemotherapy and CHILD 5 mg/m2 body Injection X radiotherapy surface IV over 15 minutes immediately before ii) Postoperative nausea and chemotherapy followed by 4 mg orally every 12 hours for vomiting up to 5 days ii) Prevention : 4 mg given by i) Prevention of nausea and IV at induction of vomiting induced by anaesthesia. CHILD over 2 years, 100 mcg/kg (max1140 Ondansetron 4 mg Tablet A04AA01110T1001X A chemotherapy and 4mg) by slow IV before,1141 Ondansetron 8 mg Tablet X radiotherapy during or after induction of ii) Postoperative nausea and anaesthesia. Treatment of postoperative: 4 mg by IM or vomiting slow. CHILD over 2 years 100 mcg/kg (maximum 4mg) i) Prevention of nausea and by slow IV i) 8 mg 1 - 2 hours before vomiting induced by treatment then 8 mg every 12 A04AA01110T1002X chemotherapy and hours for up to 5 days. X A radiotherapy CHILD, treatment by infusion followed by 4 mg by mouth ii) Postoperative nausea and every 12 hours for up to 5 vomiting days ii) Prevention of postoperative nausea and vomiting, 16 mg 1 hour before anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg at intervals of 8 hours for a further 2 doses i) 8 mg 1 - 2 hours before treatment then 8 mg every 12 hours for up to 5 days. CHILD, treatment by infusion followed by 4 mg by mouth every 12 hours for up to 5 days ii) Prevention of postoperative nausea and vomiting, 16 mg 1 hour before anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg at intervals of 8 hours for a further 2 dosesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 208 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1142 Ondansetron 8 mg/4ml A04AA01110P3002X i) Prevention of nausea and i) 8 mg given by IV infusion Injection X A vomiting induced by over 15 minutes or by IM chemotherapy and immediately before treatment1143 Oral Rehydration Salt A07CA00905F2101X C radiotherapy followed by 8 mg orally every X A ii) Postoperative nausea and 12 hours for up to 5 days.1144 Orphenadrine 100 mg A vomiting CHILD 5 mg/m2 body Tablet M03BC01110T1001 surface IV over 15 minutes XX A* Replacement of fluid and immediately before1145 Ortho-phthalaldehyde electrolytes loss in diarrhoea chemotherapy followed by 4 0.55% Solution V07AV00000L9909X mg orally every 12 hours for X Painful muscle spasm up to 5 days1146 Oxaliplatin 50 mg Injection ii) Prevention : 4 mg given by L01XA03000P4001X High level disinfectant for IV at induction of X sensitive endoscopes or anaesthesia. CHILD over 2 semi-critical reusable medical years, 100 mcg/kg (max devices 4mg) by slow IV before, during or after induction of Only for patients with anaesthesia. Treatment of colorectal cancer who: postoperative: 4 mg by IM or i) have relapsed within 6 slow. CHILD over 2 years months after the end of 100 mcg/kg (maximum 4mg) adjuvant chemotherapy with by slow IV 5-fluorouracil-based regime ADULT: 200 - 400 ml (1 - 2 ii) have progressive disease sachets) for every loose despite 5-fluorouracil motion. CHILD: 200 ml (1 chemotherapy for advanced sachet) for every loose disease motion. In severe iii) good performance status dehydration 100 ml/kg for 3 - (WHO of 2 or less). The 4 hours. INFANT: 1 - 1.5 treatment must be given in a times their usual feed volume (50 ml per stool for small infant) Initially 150 mg daily in divided doses. Maximum: 400 mg daily Manual reprocessing, at least 12 minute immersion time at room temperature (20 degree celcius) is required. Automatic endoscope reprocessor, at least 5 minute immersion time at a minimum of 25 degree celcius is required 85 mg/m2 IV repeated every 2 weeksUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 209 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1147 Oxybutynin Chloride 5 mg G04BD04110T1001 tertiary oncology centre or ADULT: Initially 5 mg 2 - 3 Tablet XX A* have clearance in writing by times daily increased if an oncologist necessary to maximum 5 mg Oxycodone HCl 10 mg N02AA05110C1002 A* 4 times daily. ELDERLY:1148 Immediate Release XX A* For the relief of symptoms of Initially 2.5 - 3 mg twice daily, A* bladder instability associated increased to 5 mg twice daily Capsules N02AA05110T5001X A* with voiding in patients with according to response and X uninhibited neurogenic or tolerance. CHILD over 51149 Oxycodone HCl 10 mg reflex neurogenic bladder (ie years, neurogenic bladder Prolonged Release Tablet N02AA05110C1003 urgency, frequency, urinary instability: 2.5 - 3 mg twice XX leakage, urge incontinence, daily increased to 5 mg twice Oxycodone HCl 20 mg dysuria) daily to maximum 3 times1150 Immediate Release N02AA05110T5002X daily X i) As a second line drug in Capsules the management of opioid Initially 5 mg every 4 to 6 responsive, moderate to hours, increased if necessary1151 Oxycodone HCl 20 mg severe chronic cancer pain according to severity of pain, Prolonged Release Tablet ii) As a step-down analgesic usual max. 400 mg daily, but drug in post-operative some patients may require procedures (Initiated by higher doses palliative medicine physicians, oncologists, ADULT, ELDERLY and anaesthesiologists, CHILDREN more than 18 haematologists and pain years, opioid-naive patients: specialists only) 10 mg 12 hourly. Renal or hepatic impairment: 5 mg 12 Management of moderate to hourly. Titrate dose carefully, severe chronic cancer pain as frequently as once a day if non-responsive to morphine necessary, to achieve pain (in accordance with WHO relief step-wise ladder of chronic pain management) [Initiated Initially 5 mg every 4 to 6 by Chronic Pain Specialist hours, increased if necessary only] according to severity of pain, usual max. 400 mg daily, but i) As a second line drug in some patients may require the management of opioid higher doses responsive, moderate to severe chronic cancer pain ADULT, ELDERLY and ii) As a step-down analgesic CHILDREN more than 18 drug in post-operative years, opioid-naïve patients: procedures (Initiated by 10 mg 12 hourly. Renal or palliative medicine hepatic impairment: 5 mg 12 physicians, oncologists, hourly. Titrate dose carefully, anaesthesiologists, as frequently as once a day if haematologists and pain specialists only) Management of moderate to severe chronic cancer pain non-responsive to morphine (in accordance with WHO step-wise ladder of chronic pain management) [Initiated by Chronic Pain Specialist only]Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 210 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY necessary, to achieve pain relief1152 Oxycodone HCl 40 mg N02AA05110T5003X A* Management of moderate to Initially, 10 mg every 12 Prolonged Release Tablet X severe chronic cancer pain hours, increased if necessary non-responsive to morphine according to severity of pain, Oxycodone HCl 5 mg N02AA05110C1001 A* (Initiated by palliative usual max. 200 mg every 121153 Immediate Release XX medicine physicians, hours, but some patients may oncologists, require higher doses Capsules anaesthesiologists, haematologists and pain Initially 5 mg every 4 to 61154 Oxycodone Hydrochloride N02AA05110P3001X A* specialists only) hours, increased if necessary 10 mg/ml Injection X i) As a second line drug in according to severity of pain, the management of opioid usual max. 400 mg daily, but responsive, moderate to some patients may require severe chronic cancer pain higher doses ii) As a step-down analgesic drug in post-operative Adults over 18 years: The procedures following starting doses are (Initiated by palliative recommended. A gradual medicine physicians, increase in dose may be oncologists, required if analgesia is anaesthesiologists, inadequate or if pain severity haematologists and pain increases. IV Bolus: Dilute to specialists only) 1 mg/ml in 0.9% saline, 5% dextrose or water for For the treatment of injections. Administer a bolus moderate to severe pain in dose of 1 to 10 mg slowly patients with cancer and over 1-2 minutes. Doses post-operative pain. For the should not be administered treatment of severe pain more frequently than every 4 requiring the use of a strong hours. IV Infusion: Dilute to 1 opioid. mg/ml in 0.9% saline, 5% dextrose or water for injections. A starting dose of 2 mg/hour is recommended. IV PCA: Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or water for injections. Bolus doses of 0.03 mg/kg should be administered with a minimum lock-out time of 5 minutes. SC Bolus: Use as 10 mg/ml concentration. A starting dose of 5 mg is recommended, repeated at 4-hourly intervals asUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 211 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Oxycodone Hydrochloride N02AA55900T1002X The management of required. SC Infusion: Dilute X A* moderate to severe chronic in 0.9% saline, 5% dextrose1155 10mg and Naloxone A* pain unresponsive to non- or water for injections if Hydrochloride Dihydrate N02AA05110T5301X narcotic analgesics. The required. A starting dose of X opioid antagonist naloxone in 7.5 mg/day is recommended 5mg Tablet the fixed combination is in opioid naïve patients, added to counteract and/or titrating gradually according Oxycodone Hydrochloride prevent opioid-induced to symptom control. Cancer1156 10mg Controlled Release constipatio. For pain patients transferring from oral specialist only oxycodone may require much Tablet higher doses (see below). Management of moderate to Transferring patients severe chronic cancer pain between oral and parenteral non-responsive to morphine oxycodone: The dose should in accordance with WHO be based on the following step-wise ladder of chronic ratio: 2 mg of oral oxycodone pain management. (Initiated is equivalent to 1 mg of by palliative medicine parenteral oxycodone. It physicians, oncologists, must be emphasised that this anaesthesiologists, is a guide to the dose haematologists and pain required.Inter-patient specialists only) variability requires that each patient is carefully titrated to the appropriate dose. Adults and paediatric patients from 18 years of age: The usual starting dose for opioid- naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief. Adults, elderly and children over 12 years: Usual starting dose for opioid-naive patients or patients presenting with moderate to severe pain uncontrolled by weaker opioids (especially if they are receiving concurrent sedatives, muscle relaxants or other CNS medicines) is 10mg 12 hourly. The dose should then be carefully titrated with longitudinal patient monitoring, assessing whether the pain is opioidUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 212 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Oxycodone Hydrochloride N02AA55900T1003X The management of responsive and providing the 20mg and Naloxone X A* moderate to severe chronic patient significant pain relief.1157 Hydrochloride Dihydrate pain unresponsive to non- Patients with renal or hepatic N02AA05110T5302X A* narcotic analgesics. The impairment: The 10mg Tablet X opioid antagonist naloxone in recommended adult starting the fixed combination is dose should be reduced by Oxycodone Hydrochloride added to counteract and/or 1/3 to 1/2, and each patient1158 20mg Controlled Release prevent opioid-induced should be titrated to constipatio. For pain adequate pain control Tablet specialist only according to their clinical situation. Management of moderate to severe chronic cancer pain Adults and paediatric patients non-responsive to morphine from 18 years of age: The in accordance with WHO usual starting dose for opioid- step-wise ladder of chronic naïve patients or patients pain management. (Initiated presenting with moderate to by palliative medicine severe chronic pain physicians, oncologists, uncontrolled by weaker anaesthesiologists, opioids is one tablet haematologists and pain 10mg/5mg at 12 hourly specialists only) intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief. Adults, elderly and children over 12 years: Usual starting dose for opioid-naive patients or patients presenting with moderate to severe pain uncontrolled by weaker opioids (especially if they are receiving concurrent sedatives, muscle relaxants or other CNS medicines) is 10mg 12 hourly. The dose should then be carefully titrated with longitudinal patient monitoring, assessing whether the pain is opioid responsive and providing the patient significant pain relief. Patients with renal or hepatic impairment: The recommended adult starting dose should be reduced by 1/3 to 1/2, and each patient should be titrated to adequate pain control according to their clinical situation.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 213 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Adults and paediatric patients from 18 years of age: The usual starting dose for opioid- naïve patients or patients The management of presenting with moderate to moderate to severe chronic severe chronic pain pain unresponsive to non- uncontrolled by weaker Oxycodone Hydrochloride narcotic analgesics. The opioids is one tablet 40mg and Naloxone N02AA55900T1004X opioid antagonist naloxone in 10mg/5mg at 12 hourly1159 Hydrochloride Dihydrate X A* the fixed combination is intervals, or one tablet 20mg Tablet added to counteract and/or 5mg/2.5mg 12-hourly for prevent opioid-induced patients with mild hepatic constipation. For pain impairment and patients with specialist only renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief. Adults, elderly and children over 12 years: Usual starting dose for opioid-naive patients or patients presenting with moderate to severe pain uncontrolled by weaker opioids (especially if they are receiving concurrent Oxycodone Hydrochloride N02AA05110T5303X A* Management of moderate to sedatives, muscle relaxants1160 40mg Controlled Release X severe chronic cancer pain or other CNS medicines) is non-responsive to morphine 10mg 12 hourly. The dose Tablet in accordance with WHO should then be carefully step-wise ladder of chronic titrated with longitudinal pain management (Initiated patient monitoring, assessing by palliative medicine whether the pain is opioid physicians, oncologists, responsive and providing the anaesthesiologists, patient significant pain relief. haematologists and pain Patients with renal or hepatic specialists only) impairment: The recommended adult starting dose should be reduced by 1/3 to 1/2, and each patient should be titrated to adequate pain control according to their clinical situation. Adults and paediatric patients Oxycodone Hydrochloride 5 The management of from 18 years of age: The moderate to severe chronic usual starting dose for opioid-1161 mg and Naloxone N02AA55900T1001X A* pain unresponsive to non- naïve patients or patients Hydrochloride Dihydrate X narcotic analgesics. The presenting with moderate to 2.5mg Tablet opioid antagonist naloxone in severe chronic pain the fixed combination is uncontrolled by weaker added to counteract and/or opioids is one tablet prevent opioid-induced 10mg/5mg at 12 hourly constipation. For pain intervals, or one tablet specialist only 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients withUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 214 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.1162 Oxymetazoline HCI 0.01% R01AA05110D6003 A* Acute cold, paranasal Newborn (up to 4 weeks): 1 Nasal Drops XX sinusitis, syringitis, otitis drop. Infant (1 - 12 month): 1 media. - 2 drop. Doses to be given twice or three times daily1163 Oxymetazoline HCl 0.025% R01AA05110D6001 A/KK Acute colds, paranasal 1 - 2 drops twice daily in (Paediatric) Nasal Drops XX sinusitis and otitis media each nostril for child more than 1 year1164 Oxymetazoline HCl 0.025% R01AA05110A4101X A Acute colds, paranasal 2 - 3 sprays into each nostril (Paediatric) Nasal Spray X sinusitis and otitis media twice daily for child more than 1 year1165 Oxymetazoline HCl 0.05% R01AA05110D6002 A/KK Acute colds, paranasal 1 - 2 drops twice daily in (Adult) Nasal Drops XX sinusitis and otitis media each nostril1166 Oxymetazoline HCl 0.05% R01AA05110A4102X A Acute colds, paranasal 2 - 3 sprays into each nostril (Adult) Nasal Spray X sinusitis and otitis media twice daily, maximum 6 sprays per nostril/day ADULT and CHILD: 1 - 51167 Oxymetholone 50 mg A14AA05000T1001X A Anaemias caused by the mg/kg daily in one daily dose. Tablet X administration of myelotoxic Usual effective dose 1 - 2 drugs, treatment of AIDS- mg/kg/day, given for a wasting syndrome minimum trial of 3 - 6 months because response may be delayed Conjunctivitis, dacryocystitis, Oxytetracycline with blepharoconjunctivitis,1168 Polymyxin B Sulphate Eye S01AA30947G5101 B keratitis, trachoma, Apply into the conjunctival XX blepharitis, pre-op sac 4 times daily Ointment prophylaxis against infection IV: 0.5 - 1 milliunits/minute; gradually increase dose in increments of 1 - 2 milliunits/minute until desired contraction pattern is1169 Oxytocin 10 units/ml H01BB02000P3001X B Induction of labour established; dose may be Injection X decreased after desired frequency of contractions is reached and labor has progressed to 5 - 6 cm dilation i) 1 ml IM, may be repeated after 2 hours. Should not exceed 3 ml within 24 hours Oxytocin 5 units & G02AC01900P3001 C+ i) Prevention and treatment ii) For routine management of1170 Ergometrine Maleate 0.5 XX of post partum haemorrhage third stage of labour, 1 ml IM ii) Management of third stage following delivery of the mg/ml Injection of labour anterior shoulder or immediately after delivery of the childUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 215 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Treatment of recurrent breast cancer, after failure of i) 175 mg/m2 IV over 3 hours anthracycline-based every 3 weeks chemotherapy ii) 175 mg/m2 IV over 3 hour ii) Primary adjuvant therapy followed by cisplatin 751171 Paclitaxel 100 mg/16.6 ml L01CD01000P3002X A* in advanced ovarian cancer mg/m2 in every 3 weeks or Injection X in combination with cisplatin 135 mg/m2 IV over 24 hours iii) Treatment of locally followed by cisplatin 75 advanced or metastatic non- mg/m2 every 3 weeks small cell lung cancer iii) 135 mg/m2 IV over 24 (NSCLC) in chemonaive hours followed by cisplatin 75 patients in combination with mg/m2 every 3 weeks platinum compounds i) Treatment of recurrent breast cancer, after failure of i) 175 mg/m2 IV over 3 hours anthracycline-based every 3 weeks chemotherapy ii) 175 mg/m2 IV over 3 hour ii) Primary adjuvant therapy followed by cisplatin 751172 Paclitaxel 30 mg/5 ml L01CD01000P3001X A* in advanced ovarian cancer mg/m2 in every 3 weeks or Injection X in combination with cisplatin 135 mg/m2 IV over 24 hours iii) Treatment of locally followed by cisplatin 75 advanced or metastatic non- mg/m2 every 3 weeks small cell lung cancer iii) 135 mg/m2 IV over 24 (NSCLC) in chemonaive hours followed by cisplatin 75 patients in combination with mg/m2 every 3 weeks platinum compounds Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Second or third line treatment Monthly dose of 75 mg eq1173 Paliperidone 100 mg N05AX13000P2004X A* of acute and maintenance (this can be increased or Prolonged Release Injection X treatment of schizophrenia in decreased based on adults individual patient’s tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Second or third line treatment Monthly dose of 75 mg eq1174 Paliperidone 150 mg N05AX13000P2005X A* of acute and maintenance (this can be increased or Prolonged Release Injection X treatment of schizophrenia in decreased based on adults individual patient’s tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle ADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -121175 Paliperidone 3 mg N05AX13000T5001X A* Second or third line treatment mg daily. Renal impairment Extended Released Tablet X of schizophrenia (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinineUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 216 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY clearance less than 10mL/min Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Second or third line treatment Monthly dose of 75 mg eq1176 Paliperidone 50 mg N05AX13000P2002X A* of acute and maintenance (this can be increased or Prolonged Release Injection X treatment of schizophrenia in decreased based on adults individual patient’s tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle ADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -121177 Paliperidone 6 mg N05AX13000T5002X A* Second or third line treatment mg daily. Renal impairment Extended Released Tablet X of schizophrenia (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Second or third line treatment Monthly dose of 75 mg eq1178 Paliperidone 75 mg N05AX13000P2003X A* of acute and maintenance (this can be increased or Prolonged Release Injection X treatment of schizophrenia in decreased based on adults individual patient's tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle ADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment1179 Paliperidone 9 mg N05AX13000T5004X A* Second or third line treatment (creatinine clearance Extended Released Tablet X of schizophrenia between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min For the prevention of serious Palivizumab 100mg lower respiratory tract Injection J06BB16000P3001X disease caused by 15 mg/kg IM once a month1180 X A* respiratory syncytial virus during season of RSV risk (RSV) in paediatric patients at high risk of RSV disease1181 Pamidronate Disodium 30 M05BA03520P3001 A* Hypercalcaemia of Dose depends on the initial mg Injection XX malignancy (tumour -induced serum calcium levels. Doses hypercalcaemia) range from a single infusion of 30 - 90 mg1182 Pamidronate Disodium 90 M05BA03520P3002 A* Hypercalcaemia of Dose depends on the initial mg Injection XX malignancy (tumour -induced serum calcium levels. Doses hypercalcaemia)Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 217 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY range from a single infusion of 30 - 90 mg Treatment of pancreatic1183 Pancreatin 150 mg Capsule A09AA02000C1001X A/KK exocrine insufficiency due to Initially 1 - 2 capsules with X conditions such as cystic each meal. May increase to 5 fibrosis, chronic pancreatitis - 15 capsules daily and non-pancreatic diseases ADULT: Initially 50 - 100 mcg/kg IV, then 10 - 201184 Pancuronium Bromide 2 mg M03AC01320P3001 Muscle relaxant as an mcg/kg as required. CHILD > / ml lnjection XX B adjunct to general 2 YEARS: Initially 60 - 100 mcg/kg then 10 - 20 mcg/kg. anaesthesia Intensive care, by IV, 60 mcg/kg every 60 - 90 minutes 40 mg twice daily until oral1185 Pantoprazole 40 mg A02BC02000P3001X A* Bleeding peptic ulcer and administration can be Injection X acute stress ulceration resumed. CHILD not recommended i) 40 mg twice daily in combination with any of the 2 antibiotics (Clarithromycin i) Helicobacter pylori 500 mg twice daily, eradication Amoxicillin 1 g twice daily or ii) Peptic ulcer disease Metronidazole 400 mg twice iii) Erosive and non-erosive daily) for 1-2 weeks1186 Pantoprazole 40 mg Tablet A02BC02000T1001X A* reflux oesophagitis (GERD ii) 40 mg daily for 2 - 4 weeks X and NERD) iii) 20 - 40 mg daily on iv) Zollinger-Ellison morning for 4 weeks Syndrome v) Prevention of iv) Initially 80 mg daily, dose NSAID induced gastropathy can be titrated up or down as needed. v) 20 mg daily. CHILD not recommended Relief of cerebral and peripheral ischaemia ADULT: 30 - 120 mg may be Papaverine HCl 120 A03AD01110P3002X associated with arterial repeated every 3 hours as1187 mg/10ml Injection X A spasm and myocardial necessary. CHILD: 6 mg/kg ischaemia complicated by daily in 4 divided doses arrhythmias Body Weight (BW) ≤ 10kg: 7.5mg/kg, max: 30mg/kg BW >10kg to ≤ 33kg: 15mg/kg, max 60mg/kg not exceeding 2g BW >33kg to ≤ 50kg: Paracetamol 10mg/ml in N02BE01000P3101X A Mild to moderate pain and 15mg/kg, max 60mg/kg not1188 100ml Solution for IV X pyrexia exceeding 3g BW >50kg (with risk of hepatotoxicity): Infusion 1g, max 3g BW >50kg (without risk of hepatotoxicity): 1g, max 4g OR as in the product leaflet CHILD: up to 1 year: 60 - 120 mg. 1 - 5 years: 120 - 2401189 Paracetamol 120 mg/5 ml N02BE01000L9001X C+ Mild to moderate pain and mg. 6 - 12 years: 240 - 480 Syrup X pyrexia mg per dose. Repeat every 4 - 6 hours when necessary.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 218 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Maximum of 4 doses in 24 hours ADULT & CHILDREN more than 12 years old: 500mg - 1g every 4-6 hours CHILD 6 - 12 years : 250 - 500 mg; 1 - 5 years : 125 - 250 mg; 3 - 11 N02BE01000S2002X Symptomatic relief of fever months : 80 mg inserted Paracetamol 125 mg X and post operative pain every 4 - 6 hours if1190 Suppository C+ whom cannot tolerate oral necessary, maximum 4 preparations. doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable. ADULT & CHILDREN more than 12 years old: 500mg - 1g every 4-6 hours CHILD 6 - 12 years : 250 - 500 mg; 1 - 5 years : 125 - 250 mg; 3 - 11 Symptomatic relief of fever months : 80 mg inserted1191 Paracetamol 250 mg N02BE01000S2001X B and post operative pain every 4 - 6 hours if Suppository X whom cannot tolerate oral necessary, maximum 4 preparations. doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable.1192 Paracetamol 500 mg Tablet N02BE01000T1001X C+ Mild to moderate pain and ADULT: 500 - 1000 mg every X pyrexia 4 - 6 hours, maximum of 4 g daily Paradichlorobenzene, S02DA30900D1001 B Occlusion or partial occlusion Instill 5 drops into the ears1193 Turpentine Oil and XX of the external auditory meatus by soft wax or wax Chlorbutol Ear Drops plug1194 Paraffin Mole Alba (White D02AC00000G5001 C Xerosis and ichthyosis Apply to the affected area Soft Paraffin) XX1195 Paraffin Mole Flava D02AC00000G5002 C Xerosis and ichthyosis Apply to the affected area XX The usual intramuscular dose of paraldehyde for status epilepticus is 0.15 to 0.3 milliliter/kilogram, a moderate additional dose (0.051196 Paraldehyde Injection N05CC05000P3001 C Status epilepticus milliliter/kilogram) may be XX necessary. The dose may be repeated in 2 to 6 hours and no more than 5 milliliters should be administered in one siteUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 219 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 40 mg followed by 20 or 40 mg every 6 to 12 hours, as1197 Parecoxib Sodium 40mg M01AH04520P3001 A* Management of post required. Use limited to two Injection XX operative pain in the days only with a maximum immediate post operative dose of 80 mg/day. Reduce setting only the initial dose by 50% in elderly less than 50 kg Recommended dose is 800 mg ORALLY once daily. For treatment of advanced Should be taken without food1198 Pazopanib Hydrochloride L01XE11110T1001X A* and/or metastatic renal cell (at least one hour before or 200 mg Tablet X carcinoma (RCC) two hours after meal). The dose should not exceed 800 mg. Recommended dose is 800 mg ORALLY once daily.1199 Pazopanib Hydrochloride L01XE11110T1002X A* For treatment of advanced Should be taken without food 400 mg Tablet X and/or metastatic renal cell (at least one hour before or carcinoma (RCC) two hours after meal). The dose should not exceed 800 mg. Administered as a slow (one1200 Pefloxacin 400 mg Injection J01MA03196P3001X A Infections due to gram- hour) intravenous perfusion, X positive and gram-negative after diluting the contents of pathogens the 400 mg in 250 ml 5% glucose (two perfusions daily, morning and evening) i) Infections due to gram-1201 Pefloxacin 400 mg Tablet J01MA03000T1001X A positive and gram-negative ADULT i) 800 mg/day in 2 X pathogens divided doses ii) Uncomplicated UTI, ii) 800 mg stat chancroid gonococcal urethritis Adults (≥18 years): One 6 mg dose (a single pre-filled syringe) of pegfilgrastim for each chemotherapy cycle, administered as a subcutaneous injection Pegfilgrastim Pre-filled L03AA13000P5001X A* Reduction in the duration of approximately 24 hours1202 Syringe 6 mg/0.6 ml (10 X neutropenia, the incidence of following cytotoxic febrile neutropenia and the chemotherapy. Renal mg/ml) incidence of infection as impairment: manifested by febrile neutropenia in patients Pharmacokinetics of treated with cytotoxic pegfilgrastim is not expected chemotherapy for malignancy to be affected by renal (with the exception of chronic impairment. Hepatic myeloid leukaemia and impairment: myelodysplastic syndromes) Pharmacokinetics of pegfilgrastim is not expected to be affected by hepatic impairment. Paediatric population: Insufficient data to recommend the use of pegfilgrastim in children and adolescents under 18 years of age.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 220 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Combination therapy with Ribavirin: ADULT: SC 1.5 mcg/kg/week CHILD and ADOLESCENT (3-17 yr): SC1203 Peginterferon Alfa-2b 80 L03AB10000P5002X A* Treatment of: 60 mcg/m2/week for 24-48 mcg Injection X i) Chronic Hepatitis C weeks Monotherapy: ADULT: ii) Chronic Hepatitis B SC 1 mcg/kg/week for 24 weeks to 1 year ii) SC 1.0 - 1.5 mcg/kg once weekly for 52 weeks i) Chronic hepatitis C usually in combination with ribavirin (Important to establish1204 Peginterferon Alpha-2a 135 L03AB11000P5002X A* i) 180 mcg weekly SC with mcg Prefilled Syringe X hepatitis C virus (HCV) genotype and viral load ribavirin 800 mg daily for 24 where combination treatment weeks in patients in genotype is advocated) 2 and 3 and 180 mcg weekly ii) For the treatment of both SC with ribavirin (1000 - HbeAg-positive and HbeAg- 1200 mg) for 48 weeks for negative chronic hepatitis B those with genotype 1 and 4. with compensated liver 135 mg dose may be used disease and evidence of viral for patients who cannot replication who are not tolerate the 180 mcg dose responding or tolerating oral ii) 180 mcg weekly SC for 48 antiviral therapy (Initiated by weeks Hepatologist and Gasteroenterologist only) i) Chronic hepatitis C usually in combination with ribavirin1205 Peginterferon Alpha-2a 180 L03AB11000P5001X A* (Important to establish i) 180 mcg weekly with mcg Prefilled Syringe X hepatitis C virus (HCV) ribavirin 800 mg daily for 24 genotype and viral load weeks in patients in genotype where combination treatment 2 and 3 and 180 mcg weekly is advocated) with ribavirin (1000 - 1200 ii) For the treatment of both mg) for 48 weeks for those HbeAg-positive and HbeAg- with genotype 1 and 4. 135 negative chronic hepatitis B mg dose may be used for with compensated liver patients who cannot tolerate disease and evidence of viral the 180 mcg dose replication who are not ii) 180 mcg subcutaneously responding or tolerating oral once a week for 48 weeks antiviral therapy (Initiated by Hepatologist and Gasteroenterologist only) i) Monotherapy: SC at a dose of 0.5 or 1 mcg/kg once weekly for at least 6 months. Combination therapy: 1.51206 Pegylated Interferon Alpha- L03AB10000P5003X A* Treatment of: mcg/kg/week SC in 2b 100 mcg Injection X i) Chronic Hepatitis C combination with ribavirin ii) Chronic Hepatitis B capsules. ii) 1-1.5 mcg/kg once weekly for at least 24 weeks and up to 52 weeks.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 221 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE L03AB10000P5004X CATEGORY i) Monotherapy: SC at a dose1207 Pegylated Interferon Alpha- X Treatment of: of 0.5 or 1 mcg/kg once 2b 120 mcg Injection A* i) Chronic Hepatitis C weekly for at least 6 months. L03AB10000P5005X Combination therapy: 1.5 X ii) Chronic Hepatitis B mcg/kg/week SC in combination with ribavirin1208 Pegylated Interferon Alpha- L03AB10000P5001X Treatment of: capsules. 2b 150 mcg Injection X A* i) Chronic Hepatitis C ii) 1-1.5 mcg/kg once weekly for at least 24 weeks and up L01DB01110P3003X ii) Chronic Hepatitis B to 52 weeks. X1209 Pegylated Interferon Alpha- Treatment of: i) Monotherapy: SC at a dose 2b 50 mcg Injection A* i) Chronic Hepatitis C of 0.5 or 1 mcg/kg once weekly for at least 6 months. ii) Chronic Hepatitis B Combination therapy: 1.5 mcg/kg/week SC in1210 Pegylated Liposomal i) For patients with platinum- combination with ribavirin Doxorubicin HCl 20 mg/vial resistant ovarian cancer capsules. where the disease relapses ii) 1-1.5 mcg/kg once weekly within 6 months after for at least 24 weeks and up completion of the initial to 52 weeks. platinum-based chemotherapy i) Monotherapy: SC at a dose ii) For patients with platinum- of 0.5 or 1 mcg/kg once sensitive ovarian cancer weekly for at least 6 months. Combination therapy: 1.5 A* where the disease responds mcg/kg/week SC in to first-line platinum-based combination with ribavirin therapy but relapses 12 capsules. months or more after ii) 1-1.5 mcg/kg once weekly completion of the initial for at least 24 weeks and up platinum based to 52 weeks. chemotherapy. As third line therapy for very selected 50 mg/m2 IV every 4 weeks patients. (Gyne Oncology for as long as the disease Specialist only) does not progress & patient continues to tolerate treatment.For doses <90 mg: dilute in 250 ml Dextrose 5 % in Water. For doses >90 mg: dilute in 500 ml Dextrose 5 % in Water. To minimize the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute. Renal impairment: No dose adjustment required in patients with creatinine clearance 30-156 ml/min, no pharmacokinetic data are available in patients with creatinine clearance of less than 30 ml/min. Hepatic impairment: At initiation of therapy: Bilirubin 1.2 - 3.0 mg/dl, the first dose is reduced by 25 %, Bilirubin > 3.0 mg/dl, the first dose is reduced by 50 %.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 222 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Initial therapy 500 mg/m (2) In combination with Cisplatin IV over 10 minutes on day 1, for the 2nd line treatment of followed 30 minutes later by patients with locally cisplatin 75 mg/m(2) infused1211 Pemetrexed Disodium 100 L01BA04016P3002X A* advanced or metastatic non IV over 2 hours; repeat cycle mg Injection X small cell lung cancer every 21-days. Prior (NSCLC) other than chemotherapy : 500 mg/m(2) predominantly squamous cell IV, as a single-agent, over 10 histology minutes on day 1 of each 21- day cycle Initial therapy 500 mg/m(2) IV In combination with Cisplatin over 10 minutes on day 1, for the 2nd line treatment of followed 30 minutes later by patients with locally cisplatin 75 mg/m(2) infused Pemetrexed Disodium 500 L01BA04016P3001X advanced or metastatic non IV over 2 hours; repeat cycle1212 mg Injection X A* small cell lung cancer every 21-days. Prior (NSCLC) other than chemotherapy : 500 mg/m(2) predominantly squamous cell IV, as a single-agent, over 10 histology minutes on day 1 of each 21- day cycle1213 Pentamidine Isethionate P01CX01198P3001X A* Only for the treatment of 4 mg/kg once daily by slow 300 mg Injection X pneumonia due to IV infusion for at least 14 Pneumocytosis carinii days1214 Pentoxifylline 400 mg C04AD03000T1001X A/KK Peripheral vascular disease 400 mg 2 - 3 times daily Tablet X1215 Peracetic Acid and V07AV00000L9906X A High level disinfectant or Immersion time based on Hydrogen Peroxide X sterilant for heat labile manufacturer endoscopes recommendation Essential hypertension, for One tablet daily, preferably patients whose blood taken in the morning and1216 Perindopril 4 mg and C09BA04900T1001X A/KK pressure is insufficiently before a meal. Indapamide 1.25 mg Tablet X controlled by perindopril alone. i) 4 mg as single dose, may be increased to a single 8 mg dose. ELDERLY: Start treatment with 2 mg dose. In renal insufficiency, dose should be adapted according to creatinine clearance ii) Single starting oral dose of i) Hypertension 2 mg should be increased to1217 Perindopril 4 mg Tablet C09AA04000T1001X B ii) Congestive heart failure a single 4 mg once BP X iii) Stable coronary artery acceptability has been disease demonstrated iii) 4 mg once daily for 2 weeks, may be increased to 8 mg once daily. ELDERLY: 2 mg once daily for 1 week, then 4 mg once daily for the following week, may be increased up to 8 mg once daily i) Hypertension i) 4 mg as single dose, may1218 Perindopril 8 mg Tablet C09AA04000T1002X B ii) Congestive heart failure be increased to a single 8 mg X iii) Stable coronary artery dose. ELDERLY: Start disease treatment with 2 mg dose. InUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 223 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY renal insufficiency, dose1219 Peritoneal Dialysis Solution B05DB00908H2001 For chronic renal disease should be adapted according (1.5% Dextrose 5 Litres) XX B requiring dialysis and for to creatinine clearance ii) Single starting oral dose of1220 Peritoneal Dialysis Solution B05DB00908H2002 acute renal failure 2 mg should be increased to (4.25% Dextrose, 2 Litres) XX a single 4 mg once BP For chronic renal disease acceptability has been1221 Peritoneal Dialysis with B05DB00908H2003 B requiring dialysis and for demonstrated 7.5% Icodextrin Solution XX iii) 4 mg once daily for 2 acute renal failure weeks, may be increased to 8 mg once daily. ELDERLY: As a once replacement for a 2 mg once daily for 1 week, single glucose exchange as then 4 mg once daily for the part of a continuous following week, may be ambulatory peritoneal increased up to 8 mg once dialysis (CAPD) or daily A* automated peritoneal dialysis (APD) regimen for the Dose depending on clinical treatment of chronic renal cases failure, particularly for patients who have lost ultra Dose depending on clinical filtration on glucose solutions cases1222 Permethrin 5% w/v Lotion P03AC04000L6001X A* Treatment of scabies Administered as a single1223 Perphenazine 4 mg Tablet X daily exchange for the long dwell in continuous N05AB03000T1001X B Schizophrenia and other ambulatory peritoneal X psychoses dialysis or automated peritoneal dialysis. The For relief of moderate to recommended dwell time is 8 severe pain (medical and to 16 hours1224 Pethidine HCl 100 mg/2 ml N02AB02110P3002X B surgical), pre-anaesthetic Injection X medication and obstetrical Apply thoroughly to all body parts. Leave on for 8 - 14 analgesia hours. Not recommended for children less than 2 years old For relief of moderate to ADULT: Initially 4 mg 3 times daily adjusted according to1225 Pethidine HCl 50 mg/ml N02AB02110P3001X B severe pain (medical and response, maximum 24 mg Injection X surgical), pre-anaesthetic daily. ELDERLY: 1/4 to 1/2 medication and obstetrical adult dose. CHILD not recommended analgesia ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IMUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 224 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE N03AA02000T1002X CATEGORY1226 Phenobarbitone 30 mg Epilepsy ADULT: 60 - 180 mg daily Tablet X B on. CHILD: Up to 8 mg/kg Status Epilepticus daily1227 Phenobarbitone Sodium N03AA02520P3001X B ADULT: 10 mg/kg IV at a rate 200 mg/ml Injection X C As disinfectant of not faster than 100 A* Hypertensive episodes mg/minute. Initial maximum1228 Phenol 80% w/w Liquid D08AE03000L5001X C associated with dose does not exceeding 1 X C phaeochromocytoma gm. Daily maintenance of 1 -1229 Phenoxybenzamine HCl C 4 mg/kg/day. CHILD: 10 - 20 100 mg/2 ml Injection C04AX02110P3001X i) Treatment or prophylaxis of mg/kg/dose loading dose, X B infections caused by followed by repeated doses1230 Phenoxymethyl Penicillin susceptible organisms at 10 mg/kg/dose (strictly in 125 mg Tablet J01CE02500T1001X ii) Prophylactic, rheumatic ICU setting). Maintenance 5 - X fever 8 mg/kg/day1231 Phenoxymethyl Penicillin 125 mg/5 ml Syrup J01CE02500F2101X Treatment or prophylaxis of Use in various dilutions X infections caused by1232 Phenoxymethyl Penicillin susceptible organisms 1 mg/kg daily over at least 2 250 mg Tablet J01CE02500T1002X hours into large vein. Do not X i) Treatment or prophylaxis of repeat within 24 hours.1233 Phenylephrine HCI 2.5% infections caused by i) ADULT: 500 - 750 mg 6 Eye Drops S01FB01110D2001X susceptible organisms hourly.CHILD; up to 1 year: X ii) Prophylactic, rheumatic 62.5 mg, 1 - 5 years: 125 mg, fever 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 - 250 mg For pupillary dilation in twice daily. CHILD: 25 - 50 uveitis, for refraction without mg/kg in divided doses every cyclopegic. For fundoscopy 6 - 8 hours. Maximum: 3 and other diagnostic g/day procedures CHILD: Up to 1 year: 62.5 mg 6 hourly; 1 - 5 years: 125 mg 6 hourly; 6 - 12 years: 250 mg 6 hourly i) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 - 250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours. Maximum: 3 g/day Mydriasis and vasoconstriction: 1 drop of 2.5% or 10% solution, repeated in one hour if necessary. Chronic mydriasis: 1 drop of a 2.5% or 10% solution 2 - 3 times a day. Uveitis with posterior synechiae (treatment) or synechiae, posterior (prophylaxis): 1 drop of a 2.5% or 10% solution, repeated in one hour if necessary, not to exceed three times a day. TreatmentUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 225 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY may be continued the following day, if necessary1234 Phenylephrine HCl 10% S01FB01110D2002X B For pupillary dilation in Mydriasis and Eye Drops X uveitis, for refraction without vasoconstriction: 1 drop of cyclopegic. For fundoscopy 2.5% or 10% solution,1235 Phenytoin Sodium 100 mg N03AB02520C1002 B and other diagnostic repeated in one hour if Capsule XX procedures necessary. Chronic mydriasis: 1 drop of a 2.5%1236 Phenytoin Sodium 125 N03AB02520L8001X B Epilepsy or 10% solution 2 - 3 times a mg/5ml Suspension X day. Uveitis with posterior Epilepsy synechiae (treatment) or1237 Phenytoin Sodium 30 mg N03AB02520C1001 B synechiae, posterior Capsule XX Epilepsy (prophylaxis): 1 drop of a 2.5% or 10% solution,Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) repeated in one hour if necessary, not to exceed three times a day. Treatment may be continued the following day, if necessary ADULT and CHILD more than 6 years: 300-400 mg/day in 3 - 4 divided doses before meals. Maximum: 600 mg/day. CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day ADULT: Patients with no previous treatment may be started on 1 teaspoonful or 5 mL (125 milligrams) 3 times daily. It is then individualized to the patient. An increase to 5 teaspoonfuls (625 milligrams) may be made if necessary. CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day. Children over 6 years and adolescents may require the minimum adult dose (300mg/day). ADULT and CHILD more than 6 years: 300-400 mg/day in 3 - 4 divided doses before meals. Maximum: 600 mg/day. CHILD: Initially 5 mg/kg/day in 2 - 3 divided 226 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day1238 Phenytoin Sodium 50mg/ml N03AB02520P3001X B Status epilepticus i) Status epilepticus: ADULT lnjection X 10 - 15 mg/kg by slow IV. For supplemental ionic Maximum 50 mg/minute. Phosphate Solution B05XA09902L5001X A phosphorus for correction of Maintenance: 100 mg1239 containing Sodium Acid X hypophosphataemia orally/IV every 6 - 8 hours. A/KK CHILD 15 - 20 mg/kg by slow Phosphate 1.936 g /15 ml HA05BA5999C1001 B Liver tonic IV. Maximum: 1 - 3 XX B Miotics in chronic open-angle mg/kg/minute1240 Phyllanthus Niruri Extract B glaucoma ii) Neurosurgery 100 - 200 250 mg Capsule S01EB01110D2001X Miotics in chronic open-angle mg IM approximately at 4 X A* glaucoma hourly interval1241 Pilocarpine 1% Eye Drops Miotics in chronic open-angle S01EB01110D2002X glaucoma According to the needs of the1242 Pilocarpine 2% Eye Drops X patient Febrile neutropenia, lower1243 Pilocarpine 4% Eye Drops S01EB01110D2003X respiratory tract infection and 2 capsules to be taken orally, X severe sepsis 3 times a day, before or after meals Piperacillin 4 g & J01CR05961P3001X Infections due to1244 Tazobactam 500 mg X Pseudomonas aeruginosa 1 drop 1 - 4 times a day Injection Treatment of cerebral 1 drop 1 - 4 times a day functional impairment1245 Piperacillin Sodium 4 g J01CA12520P4002X A 1 drop 1 - 4 times a day Injection X Mild cognitive impairment, post concussional head Adult and children more than1246 Piracetam 1 g Injection N06BX03000P3001X A* syndrome, head injury 12 years: 4.5g 6 hourly, for X disorder, chronic vertigo and neutropenia adult and myoclonus children more than 50kg:1247 Piracetam 1.2 g Tablet N06BX03000T1001X A* 4.5g 6 hourly. Children less X than 50kg: 90mg/kg 6 hourly ADULT: 100 - 150 mg/kg IM/IV in divided doses. Increase to 200 - 300 mg/kg in severe infections & at least 16 g in life-threatening infections. Single dose over 2 g: IV route only. Maximum: 24 g/day. CHILD: 50-75 mg/kg/dose every 6 - 8 hourly 30 - 160 mg/kg/day orally or parenterally 2 times daily or 3 to 4 times daily. Maximum: 24 g/day Initially 7.2 g daily in 2 - 3 divided doses, increased according to response by 4.8 g daily every 3 - 4 days to maximum of 20 g daily. CHILD under 16 years not recommendedUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 227 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE1248 Piracetam 20% Solution N06BX03000L5001X CATEGORY Children with learning1249 Piribedil 50 mg Tablet disability, progressive 30 - 160 mg/kg/day orally. To X A* myoclonic epilepsy and be given 2 times daily or 3 - 41250 Piroxicam 10 mg Capsule N04BC08000T5001X A* hypoxia times daily. Maximum 24 g/day1251 Pizotifen 0.5 mg Tablet X A/KK Parkinson disease As monotherapy: 150 - 250 mg as 3 - 5 divided doses1252 Pneumococcal Vaccine M01AC01000C1001 B i) Rheumatoid arthritis, daily. As combination with L- (Polyvalent) XX osteoarthritis, ankylosing dopa therapy: 50 - 150 mg A spondylitis daily (50 mg per 250 mg of L-1253 Podophyllum 10 - 20% N02CX01253T1001X B ii) Acute musculoskeletal dopa) Paint X disorders i) 20 mg daily, maintenance A iii) Acute gout 10 - 30 mg daily, in single or1254 Policresulen 360 mg/g J07AL01000P3001X C+ divided doses Concentrate X Prophylactic treatment of ii) 40 mg daily in single or vascular headache divided doses for 2 days,1255 Poliomyelitis Oral Live D06BB04000L7001X then 20 mg daily for 7 - 14 Vaccine (10 Doses) X Prevention of pneumococcal days infections in high risk iii) 40 mg initially, then 40 mg G01AX03900L9901X subjects from the age of 2 daily in single or divided X years including patient with a doses for 4 - 6 days history of splenectomy or Starting with 0.5mg daily, the J07BF02000D5001X scheduled splenectomy dosage should be X progressively increased. The External anogenital warts average maintenance dosage is 1.5mg daily in Local treatment of cervical divided doses or as a single and vaginal inflammation and dose at night. Max dose: 4.5 tissue damage eg. discharge mg/day and 3 mg/dose. due to bacterial, trichomonal Child: >2 yr: Up to 1.5 mg and fungal infections, daily in divided doses. Max protrusions of endocervical dose: 1 mg/dose. mucosa (erosion), Primary injection: 1 single haemostasis following biopsy injection (0.5 ml) only. or excision of uterine polyps Booster: Must not be given Immunisation against within 5 years except in very poliomyelitis high risk patient who received the vaccine while under immunosuppressive treatment Apply 2 - 3 drops carefully to lesion after protecting surrounding area with vaseline. Wash off after 6 hours or if feel burning sensation and repeat 2 - 3 times weekly or once weekly For cauterization, undiluted once or twice weekly whilst for vaginal douches, to be diluted 1 part concentrate to 5 parts of water Two drops (0.1 ml). Primary immunization: 1 oral dose atUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 228 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE1256 Polycitra Syrup CATEGORY A12BA02955L9001X For treatment of calcium and 3,4 & 5 month of age.1257 Polyethylene Glycol X C uric acid stones Booster doses at 1-4 years & /Macrogol 4000 Powder A 7 years. A06AD15000F2101X B Bowel cleansing prior to The usual dose of potassium Polymyxin B Sulphate X colonoscopy, radiological citrate is 30 - 60 mEq/day 10,000 U, Neomycin A* examination or colonic orally in 3 or 4 doses with1258 Sulphate 5 mg and S02CA03991D1001 surgery. Suitable for patients meals or within 30 minutes Hydrocortisone 10 mg Ear XX B with heart failure or renal after meals. ADULT: 15 ml 3 Drops failure times daily well diluted with J02AC04000L8001X water. CHILD 5-15 ml 3 times1259 Posaconazole 40mg/ml X Treatment of bacterial daily, after meals and at Oral Suspension infection and inflammation of bedtime. A06AD10921L9902X the external auditory meatus 1 sachet dissolved in 1 L of Potassium Chloride 0.15% X water. 2-3 L of oral solution1260 w/v & Sodium Chloride Prophylaxis of invasive are required. When morning fungal infections in the surgery is planned, the oral 0.9% w/v Injection following adult patients: solution is given in the late i. Patient receiving remission- afternoon the day prior. If induction chemotherapy for surgery is scheduled in acute myelogenous leukemia afternoon, the oral solution (AML) or myelodysplastic should be given on the same syndrome (MDS) expected to day for ingestion to be result in prolonged completed three hours before neutropenia and who are at surgery high risk of developing 3 drops 3 - 4 times daily. invasive fungal infections. External auditory meatus and ii. Haematopoietic stem cell canal to be thoroughly transplant (HSCT) recipients cleansed and dried before who are undergoing high- each application but soap dose immunosuppressive should not be used as the therapy for graft versus host antibiotics may be inactivated disease and who are at high by it risk of developing invasive Prophylaxis of invasive fungal infections. fungal infections: 200mg (5ml) three times a day. The Prevention and treatment of duration of therapy is based potassium, sodium and on recovery from neutropenia chloride depletion or immunosuppression. For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with posaconazole should start several days before the anticipated onset of neutropenia and continue 7 days after the neutrophil count rises above 500cell/mm3. Increasing the total daily dose above 800mg does not further enhance the exposure to posaconazole. Dosage depends on the age, weight, clinical and biological (acid-base balance) conditions of the patient and concomitant therapy.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 229 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Maximum recommended dose of potassium is 2 to 3 mmol/kg/24hr By slow IV infusion depending on the deficit or1261 Potassium Chloride 1 g/10 B05XA01100P3001X B For the correction of severe the daily maintenance ml Injection X hypokalaemia and when requirements. 1 g diluted in sufficient potassium cannot 500 ml normal saline or be taken by mouth glucose and given slowly over 2 - 3 hours1262 Potassium Chloride 1 g/15 A12BA01100L2101X C Potassium depletion 1 g once or twice daily until ml Mixture X serum potassium is restored1263 Potassium Chloride 600 mg A12BA01100T5001X B For the treatment and ADULT: 2 - 3 tablets daily. SR Tablet X specific prevention of Severe deficiency: 9 - 12 hypokalaemia tablets daily or according to the needs of the patient1264 Potassium Citrate 3 g/10 ml A12BA02955L2101X C For systemic or urine and Citric Acid Mixture X alkalinization ADULT: 15-30 ml well diluted with water. CHILD up to 1 year: 2.5 ml 3 times daily; 1 - 5 years: 5 ml 3 times daily; 6 - 12 years: 10 ml 3 times daily. To be taken well diluted with water, after meals and at bedtime.1265 Potassium Dihydrogen B05XA06170P3001X A For treatment of Up to 10mmol phosphate Phosphate Injection X hypophosphataemia administered over 12 hours1266 Potassium Iodide Mixture H03CA00200L2101X B Pre-operative management ADULT and CHILD: 50 - 250 X of hyperthyroidism and mg 3 times daily thyrotoxicosis1267 Potassium Permanganate D08AX06362L9901X C+ Cleansing and deodorising As soaks or wet dressing 1 - 1:10,000 Solution X suppurative eczematous 3 times daily or as required reactions and wounds1268 Potassium Permanganate D08AX06362L9902X C Cleansing and deodorising As a bath once to twice daily 1:20,000 Solution X suppurative eczematous or as required reactions and wounds Povidone Iodine 10% D08AG02000L9902X B Skin operation prior to To be applied undiluted in1269 (equivalent to 1% iodine) X surgery, in cleansing open pre-operative skin Solution wounds, as an antiseptic for disinfection and general operative wounds infections antisepsis. Spread 5 ml over both hands and rub thoroughly for about 5 minutes. Rinse thoroughly.1270 Povidone Iodine 7.5% D08AG02000L9901X B As preoperative scrub for Repeat if desired. Pre- (equivalent to 0.75% iodine) X hands and skin operative use on patient: Scrub Apply scrub and rub thoroughly for about 5 minutes. Rinse off using a sterile gauze saturated with waterUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 230 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Adult: Used in combination Antidote in the treatment of with atropine. Admin atropine via IM/IV inj and repeat as organophosphorus needed until patient shows signs of atropine toxicity.1271 Pralidoxime 25 mg/ml V03AB04000P3002X B insecticide poisoning and in Maintain atropinisation for at Injection X the control of overdosage by least 48 hr. As soon as the anticholinergic drugs used in effects of atropine are the treatment of myasthenia observed, 1-2 g of pralidoxime (chloride, iodide gravis or mesilate) may be given via IM/IV inj. Repeat dose after 1 Treatment for signs and hr, then every 8-12 hr, if symptoms of advanced necessary. In severe Pramipexole N04BC05110T1001X A* idiopathic Parkinson's poisoning, continuous1272 Dihydrochloride 0.125 mg X disease. It may be used as infusion of 200-500 mg/hr monotherapy or in may be given, titrated Tablet according to response. Alternatively, pralidoxime combination with levodopa chloride may be given at an initial dose of 30 mg/kg via IV Treatment for signs and infusion over 20 minutes or IV inj over 5 minutes, symptoms of advanced followed by IV infusion at 8 mg/kg/hr. Max: 12 g/24 hr.1273 Pramipexole N04BC05110T1002X A* idiopathic Parkinson's Child: As mesilate: 20-60 Dihydrochloride 1 mg Tablet X disease. It may be used as mg/kg. Renal impairment: Dose adjustment may be monotherapy or in required. combination with levodopa Dose escalation: 0.125 mg 3 times daily on week 1 then 0.25 mg 3 times daily week 2 then 0.5 mg 3 times daily on week 3. Increase by 0.75 mg at weekly intervals if needed up to maximum of 4.5 mg/day. Patient on levodopa: Reduce dose. Renal impairment: In patient with creatinine clearance < 20ml/min, the daily dose of pramipexole should be started at 0.125 mg daily instead of 0.25mg and the maximum dose should not > 1.5 mg daily Dose escalation: 0.125 mg 3 times daily on week 1 then 0.25 mg 3 times daily week 2 then 0.5 mg 3 times daily on week 3. Increase by 0.75 mg at weekly intervals if needed up to maximum of 4.5 mg/day. Patient on levodopa: Reduced dose. Renal impairment: In patient with creatinine clearance <Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 231 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 20ml/min, the daily dose of pramipexole should be started at 0.125 mg daily instead of 0.25mg and the maximum dose should not > 1.5 mg daily Dose escalation: 0.375 mg/day on week 1, 0.75 mg/day on week 2, 1.5 mg/day on week 3. Increase Treatment for signs and by 0.75 mg at weekly Pramipexole N04BC05110T5001X A symptoms of advanced intervals if needed up to a1274 Dihydrochloride Extended X idiopathic Parkinson's max of 4.5 mg/day. Patient disease. It may be used as on l-dopa: reduce dose. Release 0.375mg Tablet monotherapy or in Renal Impairment: CrCl 30- combination with levodopa 50 mL/min Initially 0.375 mg every other day. May be increased by 0.375 mg at weekly intervals to max 2.25 mg/day Dose escalation: 0.375 mg/day on week 1, 0.75 mg/day on week 2, 1.5 mg/day on week 3. Increase Treatment for signs and by 0.75 mg at weekly symptoms of advanced intervals if needed up to a Pramipexole N04BC05110T5003X A1275 Dihydrochloride Extended X idiopathic Parkinson's max of 4.5 mg/day. Patient Release 1.5mg Tablet disease. It may be used as on l-dopa: reduce dose. monotherapy or in Renal Impairment: CrCl 30- combination with levodopa 50 mL/min Initially 0.375 mg every other day. May be increased by 0.375 mg at weekly intervals to max 2.25 mg/day Co-administered with aspirin, is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndromes1276 Prasugrel HCl 10 mg Tablet B01AC22110T1002X A* who are to be managed with Initiate treatment with a X percutaneous coronary single 60mg oral loading intervention (PCI) as follows: dose. Continue at 10mg/5mg STEMI with or without once daily with or without diabetes, UA and NSTEMI food. Patients should also with diabetes, age <75yrs take aspirin (75 mg - 325 mg) old, weight >60kg, without daily. history of TIA stroke and clinically suspected clopidogrel resistance subset. (Only to be used in Cardiology Centre as third line treatment/ adjunctive therapy).Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 232 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 10 - 20 mg once daily. Hypercholesterolaemia and Maximum: 40 mg daily. In patients concomitantly taking coronary heart disease cyclosporine, with or without intolerant or not responsive other immunosuppressive1277 Pravastatin Sodium 20 mg C10AA03520T1001X A/KK to other forms of therapy. In drugs: Initial dose is Tablet X health clinics, Pravastatin is 10mg/day and titration to higher doses should be restricted to HIV patients on performed with caution. Maximum dose 20mg/day. HAART. Initially 0.5 mg 2 - 3 times daily, the initial dose on1278 Prazosin HCl 1 mg Tablet C02CA01110T1001X B Hypertension retiring to bed at night; X increased to 1 mg 2 - 3 times daily after 3 - 7 days: further1279 Prazosin HCl 2 mg Tablet C02CA01110T1002X B Hypertension increased if necessary to X maximum 20 mg daily Initially 0.5 mg 2 - 3 times1280 Prazosin HCl 5 mg Tablet C02CA01110T1003X B Hypertension daily, the initial dose on X retiring to bed at night; increased to 1 mg 2 - 3 times1281 Pre/Post Natal Vitamin & A11AA03903C1001X C+ Vitamin and mineral daily after 3 - 7 days: further Mineral Capsule X supplement for use during increased if necessary to pregnancy and lactation maximum 20 mg daily Initially 0.5 mg 2 - 3 times1282 Pre/Post Natal Vitamin & A11AA03903T1001X C+ Vitamin and mineral daily, the initial dose on Mineral Tablet X supplement for use during retiring to bed at night; pregnancy and lactation increased to 1 mg 2 - 3 times daily after 3 - 7 days: further i) Replacement therapy for increased if necessary to maximum 20 mg daily1283 Prednisolone 3 mg/5 ml H02AB06000L9001X B primary and secondary Syrup X adrenocortical insufficiency 1 capsule daily or based on ii) Adrenogenital syndrome individual requirements iii) Other therapy 1 tablet daily or based on individual requirements i) Replacement therapy for i) 5 - 25 mg daily in divided1284 Prednisolone 5 mg Tablet H02AB06000T1001X B primary and secondary doses X adrenocortical insufficiency ii) 10 - 20 mg/m2 body ii) Adrenogenital syndrome surface daily in divided doses iii) ADULT: 5 - 60 mg daily. iii) Other therapy CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 - 8 hours or as a single daily i) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m2 body surface daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 - 8 hours or as a single dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 233 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Initially, 75 mg twice daily. May be increased to 150 mg1285 Pregabalin 150 mg N03AX16000C1002 A* i) Second line treatment of twice daily after 3-7 days. Capsules XX neuropathic pain in patients Max: 600 mg/day after an who do not response to first additional 7-day interval line drugs ii) Initially, 75 mg twice daily. ii) Fibromyalgia May be increased to 150 mg twice daily within 1 week or 225 mg twice daily. Max: 450 mg/day i) Initially, 75 mg twice daily. May be increased to 150 mg twice daily after 3-7 days.1286 Pregabalin 75 mg Capsule N03AX16000C1001 A* i) Second line treatment of Max: 600 mg/day after an XX neuropathic pain in patients additional 7-day interval who do not response to first ii) Initially, 75 mg twice daily. line drugs May be increased to 150 mg ii) Fibromyalgia twice daily within 1 week or 225 mg twice daily. Max: 450 mg/day i) 15 mg daily for 14 days, increased to higher doses or longer course if resistance in i) Treatment of malaria P.vivax occurs.1287 Primaquine 7.5 mg base P01BA03162T1001X B ii) Prophylaxis together with a ii) ADULT: 30 mg once Tablet X schizonticide such as weekly. CHILD: 0.5 mg once chloroquine weekly Child: 250 mcg/kg daily for 14 days. Should be taken with food. Take with meals to avoid GI discomfort. ADULT: Initially 1 tablet daily in the evening, increasing by1288 Primidone 250 mg Tablet N03AA03000T1001X B Epilepsy 1 tablet every 4 - 7 days to 3 X - 4 tablets daily. Maximum dosage: 1.5 g daily in divided doses. CHILD: 6 - 8 years: Up to 1/2 adult dose Hyperuricemia associated with gout and gouty arthritis M04AB01000T1001 (for cases allergic to 500 mg to 1000 mg twice1289 Probenecid 500 mg Tablet XX A allopurinol or serum uric acid daily not controlled by allopurinol alone) ADULT: 300,000 - 900,0001290 Procaine Benzylpenicillin J01CE09702P4001X B Treatment of infections due units (300 - 900 mg) IM daily. Aqueous 3 mega units (3 g) X to Penicillin G-sensitive CHILD: Up to 1 year: 150 mg Injection organisms IM daily. 1 - 5 years: 300 mg IM daily. 6 - 12 years: 600 mg IM daily ADULT: 300,000 - 900,0001291 Procaine Penicillin Fortified J01CE09702P4002X B Treatment of infections due units (300 - 900 mg) IM daily. 4 MU Injection X to Penicillin G-sensitive CHILD: Up to 1 year: 150 mg organisms IM daily. 1 - 5 years: 300 mg IM daily. 6 - 12 years: 600 mg IM daily1292 Procarbazine HCl 50 mg L01XB01110C1001X A Lymphomas Adult: Monotherapy: Initially, Capsule X 50 mg/day, increased by 50Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 234 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1293 Prochlorperazine Maleate N05AB04253T1002X i) Severe nausea and mg daily to 250-300 mg daily 5mg Tablet X B vomiting in divided doses. Continue B ii) Vertigo/labyrinthine doses until max response is1294 Prochlorperazine Mesylate N05AB04253P3001X B disorders achieved or appearance of 12.5 mg/ml Injection X A* signs of toxicity. A* i) Severe nausea and Maintenance: 50-150 mg/day1295 Procyclidine HCl 5 mg/ ml N04AA04110P3001X vomiting or 1-2 mg/kg daily until a Injection X ii) Vertigo/labyrinthine cumulative dose of at least 6 disorders g. Combination Therapy: 1001296 Progesterone 100 mg G03DA04000C1001 mg/m2 on days 1-14 of each capsule XX i) All forms of Parkinson's 4- or 6-wk cycle. Child: disease (idiopathic paralysis Initially, 50 mg/m2 daily, up1297 Progesterone 8% Vaginal G03DA04000G3001 agitants), post-encephalitis to 100 mg/m2 adjust Gel XX and arteriosclerosis according to response. ii) To control troublesome Nausea and vomiting Adult: extrapyramidal symptoms As maleate or mesilate: 20 induced by neuroleptic drugs mg, further doses are given if including pseudo- needed. Recommended parkinsonism, acute dystonic buccal dose: As maleate: 3-6 reactions and akathisia mg bid. Vertigo Adult: As maleate or mesilate: 15-30 Supplementation of the luteal mg daily, given in divided phase doses. May reduce gradually Treatment of infertility due to to 5-10 mg daily. inadequate luteal phase Recommended buccal dose: 3-6 mg bid. May be taken with or without food. Deep IM injection, 12.5 mg repeated if necessary after 6 hours and then followed by an oral dose. Not recommended in children i) Initial dose 2.5mg TDS, increasing by 2.5-5mg/day at intervals of 2 or 3 days until the optimum clinical response is achieved. Usual maintenance dose: 15- 30mg/day. Max: 60mg/day ii) Initial dose 2.5mg TDS, increasing by 2.5mg daily until symptoms are relieved. Usual maintenance dose: 10- 30mg/day. IV Emergency: 5- 10 mg. IM Emergency: 5-10 mg as a single dose, may repeat after 20 mins if needed. Max: 20 mg/day. 200-300mg daily orally. For supplementation of the luteal phase during in IVF, 400- 600mg per day in 2-3 divided doses to be insert vaginally. 90 mg intravaginally daily from day of egg retrieval till pregnancy establishedUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 235 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Oedema and inflammation in M09AB00000T1001 conjunction with other1298 Prolase Tablet XX B physical or chemotherapeutic 2 tablet 4 times daily measures By deep IM: ADULT: 25 - 50 mg, maximum 100 mg. CHILD 5 - 10 years: 6.25 -1299 Promethazine HCl 25 mg/ml R06AD02110P3001 B Allergic conditions 12.5 mg. By slow IV: 25 - 50 Injection XX mg in a solution of 2.5 mg/ml in water for injection. Maximum 100 mg1300 Promethazine HCl 5 mg/5 R06AD02110L9001X B Allergic conditions CHILD 2 - 5 years: 5 - 15 mg ml Syrup X daily 5 - 10 years : 10 - 25 mg daily Deep anaesthesia:1 or 2 drops in the (eyes) every 5 to 10 minutes for 3 to 5 doses. Proparacaine HCI 0.5% For minor surgical Ophthalmic Drops S01HA04110D2001 Topical anaesthesia in procedures: instill 1 to 21301 XX B ophthalmic procedures drops every 5 to 10 minutes for 1 to 3 doses. Tonometry and/or tonography procedure: 1 to 2 drops in each eye before procedure.1302 Propiverine HCl 15 mg G04BD06110T1001 A* Treatment of urinary ADULT: 15 mg twice daily to Tablet XX incontinence, urgency and 3 times daily, increase to 4 frequency in neurogenic times daily if required. Max detrusor overactivity dose: 60 mg daily. CHILD (detrusor hyperreflexia) and more than 5 years: 0.2 to 0.4 in idiopathic detrusor mg/kg per day in 2 divided overactivity (overactive doses bladder) Adult: Induction: 20- 40 mg by injection or infusion every 10 sec. Usual dose: 1.5-2.5 mg/kg. Maintenance: 4-12 mg/kg/hr or intermittent bolus inj of 20-50 mg. Child: >8 yr: Induction dose of 2.5 mg/kg. Maintenance dose: 9-15 Induction & maintenance of mg/kg/hr by IV infusion or1303 Propofol 10mg/ml (1%) N01AX10000P9901X A* general anaesthesia. intermittent bolus inj. Elderly: Injection X Sedation of ventilated ICU Including neurosurgical and patients debilitated patients: Infuse at a rate of 20 mg every 10 sec. Maintenance: 3-6 mg/kg/hr. Usual dose needed: 1-1.5 mg/kg. Duration of use: Can be administered for a maximum period of 7 days. Sedation: 0.3 - 4 mg/kg/hour up to 3 daysUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 236 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Adult: IV Induction and Propofol 20mg/ml (2%) N01AX10000P9902X A* Induction & maintenance of maintenance of general1304 emulsion for injection of X general anaesthesia. anesth Induction: 40 mg Sedation of ventilated ICU every 10 sec. Maintenance: infusion patients 4-12 mg/kg/hr or intermittent boluses of 20-50 mg.1305 Propranolol HCl 1 mg/ml C07AA05110P3001X A Arrhythmias and Sedation In diagnostic and Injection X thyrotoxicosis crisis surgical procedures: Initial: 6- 9 mg/kg/hr by infusion. Dysrythmias, tachycardia, Maintenance: 1.5-4.5 mg/kg/hr. For ventilated1306 Propranolol HCl 10 mg C07AA05110T1001X B hypertrophic obstructive patients: 0.3-4 mg/kg/hr. Tablet X cardiomyopathy (For Monitor lipid concentrations if duration of sedation >3 days. cardiologist only) Slow IV injection in a dose of 1 mg over 1 minute, repeated i) Hypertension if necessary every 2 minutes until a maximum of 10 mg ii) Angina has been given in conscious patients and 5 mg in patients1307 Propranolol HCl 40 mg C07AA05110T1002X B iii) Myocardial infarct under anaesthesia. CHILD: Tablet X iv) Cardiac arrhythmia 25 - 50 mcg/kg slow IV with v) Portal hypertension appropriate monitoring vi) Migraine 10 - 40 mg 3 - 4 times daily vii) Thyrotoxicosis i) Initially 80 mg twice daily increased as required to a usual range of 160 - 320 mg daily. CHILD: Initial doses of 1 mg/kg in divided doses, can be increased to 2 - 4 mg/kg/day in divided doses ii) Initial dose of 40 mg 2 - 3 times daily. Maintenance 120 - 240 mg daily iii) 40mg 4 times daily for 2 - 3 days then 80 mg twice daily, beginning 5 - 21 days after infarction iv) 10 - 40 mg 3 - 4 times daily v) Initially 40 mg twice daily. The dose may be increased as required up to 160 mg twice daily vi) Initial prophylaxis dose: 40 mg 2 - 3 times daily. The dose may be increased at weekly intervals up to 160 mg daily vii) Adjunct: 10 - 40 mg 3 - 4 times daily. CHILD: Arrythmias, thyrotoxicosis: 0.25 - 0.5 mg/kg 3 - 4 times daily as requiredUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 237 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT Initially 300-450mg in1308 Propylthiouracil 50 mg H03BA02000T1001X Hyperthyroidism 8 hourly intervals (can be Tablet X B given up to 600-900mg/daily) Heparin overdose and until symptoms are controlled1309 Protamine Sulphate 10 V03AB14183P3001X B following cardiac or arterial in 1-2 months. Maintenance mg/ml Injection X surgery or dialysis 50-150mg daily for at least A procedures when required to 12-18 months. CHILDREN 6-1310 Protein Free D03AX00000G4001 A neutralize the effects of 10 years: 50-150mg. Haemodialysate 10% Jelly XX A heparin administered during CHILDREN > 10 years: 150- A extracorporeal circulation 300mg daily. All doses are to Protein Free S01XA20000G3001 be given in 3 divided doses1311 Haemodialysate 20% Eye XX Trophic lesions in patients daily. Taken with food. with arterial occlusive 5 ml slow IV injected over 10 Gel D03AX00000G5001 disease and with chronic minutes. If administered XX venous insufficiency, burn within 15 minutes of heparin Protein Free injuries, impaired wound dose, 1 mg will neutralise1312 Haemodialysate 5% D03AX00000G6001 healing, decubitus ulcers and approximately 100 units of XX skin ulcer caused by heparin. If longer time has Ointment irradiation elapsed, less protamine is Eyes disorders e.g. burns, required. Not more than 50 Protein Free scalds, ulcers, prevention mg should be injected at any1313 Haemodialysate Dental and treatment of radiation one time. The dose is dermatitis, traumatic and dependent on the amount Adhesive Paste ischaemic wound and type of heparin to be Trophic lesions in patients neutralised, its route of with arterial occlusive administration and the time disease and with chronic elapsed since it was last venous insufficiency, burn given and blood coagulation injuries, impaired wound studies. healing, decubitus ulcers and skin ulcer caused by Apply 3 - 5 times daily irradiation Painful and inflammatory Instill 1 drop 3 - 4 times daily affliction on the oral mucosa, gums and lips, teething pain, Apply 3 - 5 times daily denture pressure sores, oral and maxillofacial surgery and Apply to lesions 3 - 5 times dressing after scaling dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 238 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT and CHILD: 2 years1314 Pyrantel Pamoate 125 mg P02CC01127T1001X C Intestinal nematodes and older - single dose Tablet X 10mg/kg body weight once. Maximum 1 g1315 Pyrantel Pamoate 250 mg P02CC01127T1002X C Intestinal nematodes ADULT and CHILD: 2 years Tablet X and older - single dose 10mg/kg body weight once.1316 Pyrazinamide 500 mg J04AK01000T1001X B Tuberculosis Maximum 1 g Tablet X Adult: 20-40mg/kg daily (max 1500mg) or 50mg/kg1317 Pyridostigmine Bromide 60 N07AA02320T1001X B Myasthenia gravis biweekly (max 2000mg). mg Tablet X Children: 20-30mg/kg daily or 30-40mg/kg thrice weekly. i) Pyridoxine-dependent ADULT: 30 - 120 mg at convulsions in infant suitable intervals throughout the day, total daily dose 0.3 - ii) Sideroblastic anaemia 1.2 g. CHILD up to 6 years iii) B6-deficient anaemia in initially 30 mg, 6 - 12 years initially 60 mg, usual total1318 Pyridoxine HCl 10 mg A11HA02110T1001X C+ adult daily dose 30 - 360 mg Tablet X iv) Prophylaxis to peripheral i) INFANT 4 mg/kg daily for neuritis in isoniazid therapy short periods ii) 100 - 400 mg daily in v) Nausea and vomiting of divided doses iii) ADULT 20 - 50 mg up to 3 pregnancy and irradiation times daily sickness iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3 times i) Pyridoxine-dependent daily v) 20 - 100 mg daily convulsions in infancy i) INFANT 4 mg/kg daily for ii) Sideroblastic anaemia short periods ii) 100 - 400 mg daily in Pyridoxine HCl 50 mg/2 ml A11HA02110P3001X iii) B6-deficient anaemia in divided doses Injection X adult iii) ADULT 20 - 50 mg up to 31319 B iv) Prophylaxis to peripheral times daily iv) Prophylaxis 10 mg daily, neuritis in isoniazid therapy therapeutic 50 mg 3 times v) Nausea and vomiting of daily v) 20 - 100 mg daily pregnancy and irradiation sicknessUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 239 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Quetiapine Fumarate 100 N05AH04138T1002X i) Schizophrenia i) Initial titration schedule1320 mg Immediate Release X A* ii) Short term treatment of over 4 days: 25 mg twice acute manic episodes daily on Day 1, increase in Tablet N05AH04138T5002X A* associated with bipolar I steps of 25 - 50 mg 2 to 3 X disorder, either monotherapy times daily on Days 2 and 3 Quetiapine Fumarate 200 or adjunct to lithium or to reach target dose of 300 -1321 mg Extended Release divalproex 400 mg daily by Day 4, given iii) Treatment of depressive in 2 - 3 divided doses. Tablet episodes associated with Institute further dose bipolar disorder adjustments, if indicated, at intervals of 2 days or more, in i)Schizophrenia steps of 25 - 50 mg twice ii) Moderate to severe manic daily episodes in bipolar disorder ii) 100 mg (Day 1), 200 mg iii) Major depressive (Day 2), 300 mg (Day 3) & episodes in bipolar disorder 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of not more than 200 mg/day. Adjust dose within the range of 200 - 800 mg/day depending on clinical response and tolerability of the patient. Usual effective dose range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1, then 100 mg once daily on Day 2, then 200 mg once daily on Day 3, then 300 mg once daily on Day 4 (all doses given at bedtime); patients requiring higher doses should receive 400 mg on Day 5, increased to 600 mg on Day 8 (week 1) i) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2. Maintenance dose: 400 to 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily. In elderly or hepatic impairment:Start with 50mg/ day, may be increased in increments of 50mg /day to an effective dose.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 240 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Quetiapine Fumarate 200 N05AH04138T1004X i) Schizophrenia i) Initial titration schedule1322 mg Immediate Release X A* ii) Short term treatment of over 4 days: 25 mg twice acute manic episodes daily on Day 1, increase in Tablet N05AH04138T5003X A* associated with bipolar I steps of 25 - 50 mg 2 to 3 X A* disorder, either monotherapy times daily on Days 2 and 3 Quetiapine Fumarate 300 or adjunct to lithium or to reach target dose of 300 -1323 mg Extended Release N05AH04138T5004X divalproex 400 mg daily by Day 4, given X iii) Treatment of depressive in 2 - 3 divided doses. Tablet episodes associated with Institute further dose Quetiapine Fumarate 400 bipolar disorder adjustments, if indicated, at1324 mg Extended Release intervals of 2 days or more, in Tablet i) Schizophrenia steps of 25 - 50 mg twice ii) Moderate to severe manic daily episodes in bipolar disorder ii) 100 mg (Day 1), 200 mg iii) Major depressive (Day 2), 300 mg (Day 3) & episodes in bipolar disorder 400 mg (Day 4). Further dosage adjustments up to i) Schizophrenia 800 mg/day by Day 6 should ii) Moderate to severe manic be in increments of not more episodes in bipolar disorder than 200 mg/day. Adjust iii) Major depressive dose within the range of 200 episodes in bipolar disorder - 800 mg/day depending on clinical response and tolerability of the patient. Usual effective dose range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1, then 100 mg once daily on Day 2, then 200 mg once daily on Day 3, then 300 mg once daily on Day 4 (all doses given at bedtime); patients requiring higher doses should receive 400 mg on Day 5, increased to 600 mg on Day 8 (week 1) i) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2. Maintenance dose: 400 - 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily i) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2. Maintenance dose: 400 - 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose isUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 241 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 300 mg. May be titrated up to 600 mg daily1325 Quetiapine Fumarate 50 mg N05AH04138T5001X A* i) Schizophrenia i) & ii) 300 mg once daily on Extended Release Tablet X ii) Moderate to severe manic Day 1 then 600 mg on Day 2. episodes in bipolar disorder Maintenance dose: 400 to1326 Quinine Dihydrochloride P01BC01110P3001X B iii) Major depressive 800 mg once daily. Maximum 600 mg/2 ml Injection X episodes in bipolar disorder dose: 800 mg daily. iii) 50 mg on Day 1, 100 mg1327 Quinine Sulphate 300 mg P01BC01183T1001X B Severe and complicated on Day 2, 200 mg on Day 3 Tablet X malaria and 300 mg on Day 4. Recommended daily dose is1328 Rabeprazole Sodium 20 mg A02BC04520T1001X A* Severe and complicated 300 mg. May be titrated up to Tablet X malaria 600 mg daily. In elderly or hepatic impairment: Start Rabies Human Diploid Cell J07BG01000P4001X B i) Treatment and with 50mg/ day, may be1329 Vaccine (Lyophilised) X maintenance of erosive or increased in increments of ulcerative gastroesophageal 50mg /day to an effective Injection reflux disease (GERD) dose. ii) Duodenal ulcers Pre-exposure and post- By slow intravenous infusion exposure vaccination against (over 4 hours). ADULT: 20 rabies mg/kg followed by 10 mg/kg every 8 hours. CHILD : 20 mg/kg followed by 10 mg/kg every 12 hours, initial dose should be half in patients who have received quinine, quinidine or mefloquine during the previous 12 or 24 hours 300 - 600 mg daily. Treatment: 1.2 - 2 g daily in divided doses. CHILDS less than 1 year : 100 - 200 mg daily, 1 - 3 years : 200 - 300 mg daily, 4 - 6 years: up to 500 mg daily, more than 7 years : up to 1 g daily. All above doses are given for 7 days in 2 - 3 divided doses i) 10-20 mg daily for 4-8 weeks, maintenance 10-20 mg daily ii) 20 mg daily at morning for up to 4-8 weeks Prophylaxis: 3 dose (1 ml each) schedule on D0, D7 and D28. Booster dose after every 2 - 3 years. Post exposure prophylaxis: use after attack of a potential rabid animal: 1 dose on D0,Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 242 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY D3, D7, D14 and D28. In previously vaccinated individuals 2 doses on D0 and D3 Raloxifene HCl 60 mg G03XC01110T1001 Prevention and treatment of Tablet XX1330 A* postmenopausal 1 tablet daily osteoporosis Raltgeravir combination with1331 Raltegravir 400 mg tablet J05AX08500T1001X A* other antiretroviral agents is 400mg administered orally, X indicated for the treatment of twice daily with or without HIV-1 infection in patients food, to be given combination who are contraindicated to with other antiretroviral boosted Protease Inhibitor or agent. who are intolerant to boosted Protease Inhibitor. i) Hypertension: Initially 2.5 mg once daily, increased at intervals of 1 - 2 weeks to i) Hypertension and maximum 10 mg once daily; congestive heart failure ii) Congestive heart Post-myocardial infarction iii) failure:Initially 1.25 mg once1332 Ramipril 2.5 mg Tablet C09AA05000T1001X A Reducing risk of myocardial daily. Max: 10 mg/day ii) X infarction, stroke or Initially 2.5 mg twice daily for cardiovascular death in 2 days then increased to diabetics or patients with maximum 5 mg twice daily iii) increased cardiovascular Initially 1.25 - 2.5 mg once risks daily, increased to 5 mg once daily after 1 week, maximum dose: 10 mg once daily after 3 weeks i) Hypertension: Initially 2.5 mg once daily, increased at intervals of 1 - 2 weeks to i) Hypertension and maximum 10 mg once daily; congestive heart failure ii) Congestive heart Post-myocardial infarction iii) failure:Initially 1.25 mg once Reducing risk of myocardial daily. Max: 10 mg/day1333 Ramipril 5 mg Tablet C09AA05000T1002X A infarction, stroke or ii) Initially 2.5 mg twice daily X cardiovascular death in for 2 days then increased to diabetics or patients with maximum 5 mg twice daily increased cardiovascular iii) Initially 1.25 - 2.5 mg once risks daily, increased to 5 mg once daily after 1 week, maximum dose: 10 mg once daily after 3 weeksUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 243 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1334 Ranibizumab 10 mg/ml S01LA04000P3001X i) Treatment of Neovascular 0.5 mg (0.05ml) as a single Intravitreal Injection X A* (wet) Age-Related Macular intravitreal Injection.Interval Degeneration (ARMD). between 2 doses should not ii) Treatment of visual be shorter than 1 month, then impairment due to diabetic monitor for visual acuity macular edema (DME). monthly. Treatment is given iii) Treatment of visual monthly & continued until impairment due to macular max visual acuity is edema secondary to retinal achieved, confirmed by vein occlusion (RVO). stable visual acuity for 3 iv) Treatment of visual consecutive monthly impairment due to choroidal assessments. neovascularization (CNV) secondary to pathologic i) 150 mg twice daily (at myopia (PM). morning and night) or 300 mg Note: Indication ii) and iii) on night for 4-8 weeks. approved to be used by Maintenance: 150-300 mg on retinal specialist only night (PFUKKM 1/2015) ii) 150 mg twice daily or 300 mg on night for 8-12 weeks i) Benign gastric and iii) 150 mg daily or twice daily duodenal ulcer ii) Reflux iv) 150 mg and may be increased as necessary to 61335 Ranitidine 150 mg Tablet A02BA02110T1001X B oesophagitis g/day X iii) Non-ulcer dyspepsia CHILD 2-4 mg/kg 2 times daily. Maximum 300 mg daily iv) Zollinger-Ellison i) ADULT: Slow IV injection of 50 mg diluted to 20 ml and Syndrome given over at least 2 minutes. May be repeated every 6-81336 Ranitidine 150 mg/10 ml A02BA02110L9001X B Peptic ulcer disease hours or IV infusion at rate of Syrup X 25 mg/hour for 2 hours, may be repeated at 6-8 hours i) Benign gastric/ duodenal intervals or IM. CHILD: 1 ulceration, reflux mg/kg/dose 6-8 hourly. ii) Initial slow IV injection of1337 Ranitidine 25 mg/ml A02BA02110P3001X B oesophagitis, Zollinger 50 mg, then continuous Injection X Ellison Syndrome infusion of 125-250 ii) Stress ulcer prophylaxis in mcg/kg/hour i) 150 mg twice daily (at post-operative and high risk morning and night) or 300 mg patients on night for 4-8 weeks. Maintenance: 150-300 mg on i) Benign gastric and night ii) 150 mg twice daily or 300 duodenal ulcer mg on night for 8-12 weeks A02BA02110T1002X ii) Reflux oesophagitis iii) 150 mg daily or twice daily1338 Ranitidine 300 mg Tablet X B iii) Non-ulcer dyspepsia iv) 150 mg and may be increased as necessary to 6 iv) Zollinger-Ellison g/day SyndromeUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 244 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE1339 Remifentanil 5 mg Injection CATEGORY1340 Repaglinide 2 mg Tablet N01AH06110P4001 i) As an analgesic agent for For IV use only. ADULT: XX A* use during induction and/or Induction: Bolus infusion: maintenance of general 1µg/kg over 30-60 seconds; A10BX02000T1001X A* anaesthesia during surgical Continuous infusion: 0.5- X procedures including cardiac 1µg/kg/min; Maintenance: surgery. Continuous infusion: 0.025 to ii) Continuation of analgesia 2 µg/kg/min. CHILD (1-12 into the immediate post- years of age): Induction: operative period under close Insufficient data; Neonates: supervision, during transition IV infusion 0.4-1.0 to longer acting analgesia. mcg/kg/minute depending on iii) Provision of analgesia and the anaesthetic method and sedation in mechanically adjust according to patient ventilated intensive care response, supplemental IV inj patients. of 1 mcg/kg dose may be given. 1-12 yr: initially 0.1-1 Type 2 diabetes mellitus (as mcg/kg by IV inj over at least monotherapy or in 30 seconds (excluded if not combination with metformin needed), followed by IV when metformin alone is infusion 0.05-1.3 inadequate) mcg/kg/minute depending on the anaesthetic method and adjust according to patient response, supplemental IV bolus inj may be admin during infusion. 12-18 yr: 0.1- 1 mcg/kg IV inj over at least 30 seconds (excluded if not needed), followed by IV infusion of 0.05-2 mcg/kg/minute depending on anaesthetic method and adjust according to patient response, supplemental IV bolus inj may be admin during infusion. OHA naïve patient: Start dose with 0.5mg per meal Patients transferred from another oral hypoglycaemic agent: Start dose with 0.5- 1mg per meal In combination with metformin: Start dose as 0.5mg per meal Titrate every 1-2weeks according to blood glucose response. Max single dose: 4mg before each main meal. Max total daily dose: 16mg. Doses to be taken within 30 minutes of meals, 2-4 meals a dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 245 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT (more than 18 years old): 50mg/kg/day Recommended: Body weight: ≤ 75kg should receive 1000mg daily as two 200mg capsules in the morning and three 200mg capsules in the1341 Ribavirin 200 mg Capsule J05AB04000C1001X A* For the treatment of chronic evening Body weight: >75kg X hepatitis C (in combination should receive 1200mg as with interferon alfa-2a/2b) three 200mg capsules in the morning and three 200mg capsules in the evening Genotype 1,4: 48 weeks Genotype: 24 weeks duration should be individualized in accordance with the baseline characteristics of the disease.1342 Riboflavine 3 mg Tablet A11HA04000T1001X C For prevention and treatment CHILD: 2.5-10 mg/day in X of riboflavine deficiency divided doses. ADULT: 5-30 mg/day in divided doses CHILD: 20 mg/kg body1343 Rifampicin 100 mg/5 ml J04AB02000L9001X A Tuberculosis and leprosy weight daily in 1 - 2 doses. Syrup X Up to 1 year: 10 mg/kg body weight in a single daily dose i) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20 mg/kg body weight1344 Rifampicin 150 mg Capsule J04AB02000C1001X B i) Tuberculosis daily in 1 - 2 doses. Directly X ii) Leprosy observed therapy (DOT): 10 iii) Prophylaxis for mg/kg twice weekly or 3 meningococcal meningitis times/week. Maximum: 600 mg ii) 600 mg/day iii) 600 mg twice daily for 2 days Rifampicin 150 mg, Patient more than or 71 kg: 5 tab/day, 55 -70 kg: 4 tab/day,1345 Isoniazid 75 mg & J04AM05000T1001X B Initial phase (2 months) of 38-54 kg: 3 tab/day, 30-37 Pyrazinamide 400 mg X tuberculosis treatment kg: 2 tab/day. To be taken as Tablet a single dose Rifampicin 150 mg, J04AM06000T1001X B Treatment of both pulmonary ADULT: 30 - 37 kg: 2 tablets Isoniazid 75 mg, X and extrapulmonary daily, 38 - 54 kg: 3 tablets1346 Pyrazinamide 400 mg & daily, 55 - 70 kg: 4 tablets Ethambutol HCl 275 mg tuberculosis, in the intensive daily, more than 70 kg: 5 Tablet tablets daily treatment phase1347 Rifampicin 150mg + J04AM02000T1001X B For pulmonary tuberculosis in 30-37kg: 2 tablets once daily, Isoniazid 75mg tablet X which organisms are 38-54kg: 3 tablets once daily, susceptible in continuation 55-70kg: 4 tablets once daily, phase treatment for 4 months Above 70kg: 5 tabs once dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 246 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Tuberculosis ADULT: Daily J04AB02000C1002X i) Tuberculosis doses: 10mg/kg/day Body X ii) Leprosy weight doses: 10-15/kg/day1348 Rifampicin 300 mg Capsule B iii) Prophylaxis for CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. meningococcal meningitis Maximum daily dose: 600mg Directly observed therapy1349 Rifampicin, Dapsone & J04AM02961T9901X B For the treatment of leprosy (DOT): 10 mg/kg twice Clofazimine X and tuberculosis weekly or 3 times/week. Maximum: 600 mg Ringers Solution (contained As a source of electrolytes ii) Leprosy: ADULT: 600 mg/day CHILDREN: 10mg/kg1350 sodium chloride, potassium B05XA30905P6001X B and water for iii) Prophylaxis for chloride and calcium X hydration/replenishing of meningococcal meningitis: ADULT: 600 mg twice daily chloride) chloride for 2 days CHILDREN: 10mg/kg twice daily for 21351 Risperidone 1 mg Tablet N05AX08000T1001X B Psychoses and days INFANT: 5mg/kg twice X schizophrenia daily for 2 days\" Rifampicin: 600 mg once1352 Risperidone 1 mg/ml Oral N05AX08000L5001X A Psychoses and monthly, Dapsone: 100 mg Solution X schizophrenia daily, Clofazimine: 300 mg once monthly and 50 mg daily (or 100 mg on alternate days) According to the needs of the patient ADULT : 2 mg in 1 - 2 divided doses on first day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 8 mg daily; dose above 10 mg daily only if benefit outweigh risk (maximum 16 mg daily). Elderly (or in hepatic or renal impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1 - 2 mg twice daily. Not recommended in children under 15 years ADULT: 2 mg in 1 - 2 divided doses on 1st day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 8 mg daily; dose above 10 mg daily only if benefit outweighs risk (maximum 16 mg daily). Elderly (or in hepatic or renalUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 247 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1-2 mg twice daily. Not recommended in children under 15 years ADULT : 2 mg in 1 - 2 divided doses on first day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 81353 Risperidone 2 mg Tablet N05AX08000T1002X B Psychoses and mg daily; dose above 10 mg X schizophrenia daily only if benefit outweigh risk (maximum 16 mg daily). Elderly (or in hepatic or renal impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1 - 2 mg twice daily. Not recommended in children under 15 years Treatment of acute and chronic schizophrenic 25 mg IM every 2 weeks. psychosis and other Risperidone 25 mg Injection N05AX08000P3001X psychotic conditions, in which Dose increments (if required) (Long Acting) X1354 A* positive and negative to 37.5 mg or 50 mg can be symptoms are prominent. It considered after a minimum also alleviates affective of 4 weeks on each dosage symptoms associated with schizophrenia Treatment of acute and chronic schizophrenic 25 mg IM every 2 weeks. psychosis and other1355 Risperidone 37.5 mg N05AX08000P3002X A* psychotic conditions, in which Dose increments (if required) Injection (Long Acting) X positive and negative to 37.5 mg or 50 mg can be symptoms are prominent. It considered after a minimum also alleviates affective of 4 weeks on each dosage symptoms associated with schizophrenia Treatment of acute and chronic schizophrenic psychosis and other 25 mg IM every 2 weeks. Risperidone 50 mg Injection N05AX08000P3003X A* psychotic conditions, in which Dose increments (if required)1356 (Long Acting) X positive and negative to 37.5 mg or 50 mg can be symptoms are prominent. It considered after a minimum also alleviates affective of 4 weeks on each dosage symptoms associated with schizophrenia IV 0.05 mg/min to be gradually increased by 0.051357 Ritodrine HCl 50 mg/5 ml G02CA01110P3001 A Prevention of preterm labour mg/min every 10-15 minutes. Injection XX IM injection: 10 mg 4-6 hourly. Continue treatment for 12-48 hours after ceased contractionUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 248 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Progressive or advanced HIV ADULT: (Single PI) initially infection in combination with 300 mg twice daily, increase other antiretroviral agents. by 100 mg twice daily J05AE03000C1001X Criteria for use: a) Clinical increments to 600 mg twice1358 Ritonavir 100 mg Capsule X A* AIDS daily. (Dual PI) Initially b) CD4 less than 350 cells or 200mg BD, then increase by c) Viral load more than 100mg BD & reaching 400mg 10,000 copies/ml BD within 2 wk. Progressive or advanced HIV ADULT: 400 - 600 mg twice infection in combination with daily. CHILD: >1 month, other antiretroviral agents. initiate at dise of 25mg/m21359 Ritonavir 80 mg/ml Solution J05AE03000L9901X A* Criteria for use: a) Clinical twice daily, titrate dose X AIDS upward every 2-3 days by b) CD4 less than 350 cells or 50mg/m2 twice daily c) Viral load more than (maximum dose 600mg twice 10,000 copies/ml daily) i) 375 mg/m2 BSA i) Treatment of patients with administered as an IV relapsed or chemo-resistant infusion through a dedicated low grade or follicular B-cell line once weekly for 4 weeks Non-Hodgkin's lymphoma ii) Combination with CHOP ii) Adjunctive therapy with (cyclophosphamide, combination chemoagents for doxorubicin, prednisone and aggressive Non-Hodgkin vincristine) as 375 mg/m2 Lymphoma iii) Severe active BSA on day 1 of each rheumatoid arthritis with chemotherapy cycle for 81360 Rituximab 10 mg/ml L01XC02000P3001X A* inadequate response or cycles after IV administration Injection X intolerance to other disease- of the glucocorticoid modifying anti-rheumatic component of CHOP. drugs (DMARDs) including iii) 1000 mg IV infusion one or more tumour necrosis followed by a second 1000 factor (TNF) inhibitor mg IV infusion two weeks therapies iv) Maintenance in later iv) 375mg/m2 BSA once relapsed/ refractory follicular every 3 months until disease lymphoma after response to progression or for a induction therapy maximum period of two years. 10 mg once daily. Initial dose Prevention of venous should be taken 6 to 10 hour post-surgery provided that1361 Rivaroxaban 10 mg Tablet B01AX06000T1001X A* thromboembolism in patients haemostasis has been X undergoing elective hip or established. Duration of knee replacement surgery treatment: Major hip surgery 5 weeks. Major knee surgery 2 weeks i) Prevention of stroke and systemic embolism in adult patients with non-valvular i) 20mg once daily or 15mg atrial fibrillation with one or once daily (for patients with more risk factors, such as moderate renal impairment B01AX06000T1002X Congestive heart failure (creatinine clearance 30-491362 Rivaroxaban 15 mg Tablet X A* (CHF), hypertension, age ≥ ml/min) 75 yrs, diabetes mellitus, Dosage: ii) & (iii) 15mg BD prior stroke or transient for 21 days, followed by ischaemic attack. 20mg OD. ii) Treatment of deep vein thrombosis (DVT), andUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 249 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults. i) Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ i) 20mg once daily or 15mg 75 yrs, diabetes mellitus, prior stroke or transient once daily (for patients with ischaemic attack. moderate renal impairment1363 Rivaroxaban 20 mg Tablet B01AX06000T1003X A* ii) Treatment of deep vein (creatinine clearance 30-49 X thrombosis (DVT), and ml/min) prevention of recurrent DVT Dosage (ii) & (iii) 15mg BD and pulmonary embolism for 21 days, followed by (PE) following an acute DVT 20mg OD. in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults. Initial dose 1.5 mg 2 times daily, may increase by 1.51364 Rivastigmine 1.5 mg N06DA03123C1001 A* For psychiatrists and mg 2 times daily every 2 Capsule XX neurologists only. Mild to weeks to maximum of 6 mg 2 moderately severe dementia times daily. If treatment is associated with Alzheimer's interrupted for several days, or Parkinson's disease should be reinitiated at the lowest daily dose Initial dose 1.5 mg 2 times daily. May be increased after a minimum of 2 weeks of For psychiatrists and treatment to 3 mg 2 times neurologists only. Mild to daily. Subsequently to 4.5 mg1365 Rivastigmine 2 mg/ml Oral N06DA03123L9901X A* moderately severe dementia 2 times daily, up to maximum Solution X associated with Alzheimer's of 6 mg 2 times daily. If or Parkinson's disease treatment is interrupted for several days, should be reinitiated at the lowest daily dose1366 Rivastigmine 3 mg Capsule N06DA03123C1002 A* For psychiatrists and Initial dose 1.5 mg 2 times XX neurologists only. Mild to daily, may increase by 1.5 moderately severe dementia mg 2 times daily every 2 associated with Alzheimer's weeks to maximum of 6 mg 2 or Parkinson's disease times daily. If treatment is interrupted for several days,Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 250 / 314